

IN THE SUPERIOR COURT OF THE STATE OF WASHINGTON  
IN AND FOR THE COUNTY OF KITSAP

JOSETTE TAYLOR as Personal  
Representative of the Estate of FRED E.  
TAYLOR, deceased; and on behalf of the  
Estate of FRED E. TAYLOR; and JOSETTE  
TAYLOR, Individually,

Plaintiffs

v.

SCOTT BILDSTEN, D.O., individually, JOHN C.  
HEDGES, M.D., individually, KITSAP  
UROLOGY ASSOCIATES, P.C., a Washington  
active, for profit corporation, and INTUITIVE  
SURGICAL, INC., a foreign corporation doing  
business in Washington,

Defendants.

**NO. 09-2-03136-5**

**PLAINTIFF'S OPPOSITION TO  
INTUITIVE'S MOTION FOR  
SUMMARY JUDGMENT ON ALL  
CLAIMS**

**I. CASE OVERVIEW**

Fred Taylor was severely injured during an operation to remove his prostate gland. This operation is called a prostatectomy. Fred Taylor's operation was the first time his surgeon, Scott Bildsten, had used the da Vinci robotic system, unsupervised, to effectuate a prostatectomy. The robotic system was manufactured by ISI; Dr. Bildsten was trained in its use by ISI.

PLAINTIFF'S OPPOSITION TO ISI MOTION FOR  
SUMMARY JUDGEMENT ON ALL CLAIMS

FRIEDMAN | RUBIN  
1126 HIGHLAND AVE.  
BREMERTON, WA 98312  
PHONE (360) 782-4300  
FACSIMILE (360) 782-4358

1 Like all tort cases, this one involves questions of duty, breach, causation and damages.  
2 Because Mrs. Taylor can show genuine issues of material fact as to each element of her claims,  
3 ISI's motion for summary judgment should be denied.

4 **A. Duty**

5 A defendant's duty can arise from multiple sources, including statutes and the common  
6 law. Here, there is no dispute that the Washington Product Liability Act ("WPLA") imposes  
7 certain duties on ISI, as the manufacturer of a product, as a matter of law. *See* RCW 7.72.030.

8 There is a fact question as to whether ISI voluntarily assumed additional duties, beyond  
9 the scope of the WPLA, by creating a training program which surgeons could pay to attend  
10 whether or not they or their institution had purchased a *da Vinci* robot. Washington law  
11 recognizes that a defendant can voluntarily assume duties, beyond those that would otherwise be  
12 imposed by law. *E.g. Meneely v. S.R. Smith, Inc.*, 101 Wn.App. 845, 856; 5 P.3d 49, 55 (2000)  
13 (trade association that voluntarily undertook to issue safety standards for the protection of pool  
14 users, assumed the duty to act with reasonable care); Restatement (Second) of Torts, Section  
15 324A.

16 ISI says it did not assume a duty to train doctors. Yet, it admits that it provides each  
17 urologist it trains<sup>1</sup> with a document entitled: "The Clinical Pathway and Training Protocol for  
18 *da Vinci* Prostatectomy."<sup>2</sup> Dr. Bildsten was given such a document before he ever operated on  
19 a live patient.<sup>3</sup> The document describes a detailed training program, telling Dr. Bildsten:

20 The following clinical pathway has been put in place *to ensure success in*  
21 *becoming a proficient robotic surgeon.*

22 <sup>1</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 231:23-25 ("Q. Were there ever  
23 times when you didn't go over the clinical pathway with a surgeon? A. No.").

<sup>2</sup> PT-42, Ex. A.

<sup>3</sup> Exhibit PT-42, at 2.

1 (emphasis added).

2 After describing a detailed training regime, designed, operated and controlled by ISI, the  
3 document then requires signature from the doctor, committing to the ISI training “pathway,” in  
4 order to “*ensure* early success for Robotic Prostatectomy.”<sup>4</sup> Damon Daniels, the ISI sales rep  
5 who gave Dr. Bildsten the Clinical Pathway, admitted that he would tell the surgeons, and wanted  
6 those surgeons to believe, that the Clinical Pathway would ensure the surgeon’s success in  
7 becoming a proficient robotic surgeon.<sup>5</sup>

8 When training its salespeople, ISI defines this Clinical Pathway document as a  
9 “[p]rescribed, stepwise approach for surgeons and OR staff to develop knowledge and skills  
10 using the da Vinci Surgical System *in clinical applications*.”<sup>6</sup> In fact, the “Clinical Sales  
11 Representatives” (CSRs) understood that an ISI certification meant the surgeons had  
12 successfully completed “the protocol for their specialty” and were able to apply surgical skills  
13 “to procedural applications.”<sup>7</sup> CSRs were explicitly told: “All necessary training for surgeons  
14 and nurses is built into the clinical plan.”<sup>8</sup> In documents it gave to Harrison, ISI urged  
15 surgeons to “Follow the Prescribed Clinical Pathway.”<sup>9</sup>

16 As outlined in following sections of this brief, there are a great many additional facts  
17 showing ISI’s assumption of the duty to train Dr. Bildsten. But the facts recited above are  
18 sufficient to defeat ISI’s summary judgment motion. By “prescribing” and providing a  
19

---

20 <sup>4</sup> Exhibit PT-42, at 6 (emphasis added).

21 <sup>5</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 268:22-269:5.

22 <sup>6</sup> PT 212 (emphasis added); Exhibit A to Mullenix Declaration (Daniels Deposition) at 258:10-  
23 22; 211:17-18 (“I told [surgeons] ... here's our clinical pathway document, you know, you  
should abide by this”).

<sup>7</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 266:1-8.

<sup>8</sup> PT-30 at 10878; Exhibit B to Mullenix Declaration (Nagel Deposition) at 59:10-11.

<sup>9</sup> PT-72 at 1.

1 detailed training program for surgeons that ISI said would “ensure early success for Robotic  
2 Prostatectomy,” ISI assumed a duty beyond those imposed by statute upon manufacturers: *it*  
3 *assumed a duty to train with reasonable care.* ISI’s disclaimers to the contrary do nothing  
4 more than create a genuine factual dispute as to the assumption of the duty and its scope.

5 **B. Breach**

6 The declaration of William Scott Helton, M.D. states that the ISI training program applied  
7 to Dr. Bildsten was

8 incomplete and potentially unsafe... Further, to suggest that any surgeon could be  
9 adequately trained to perform any type of major surgery using the da Vinci surgical  
10 system after only the level of training proposed is unfounded and unsupported by  
any data, a leap of faith, potentially unsafe, and irresponsible.”<sup>10</sup>

11 While more facts showing ISI’s breach of its assumed duty to train are outlined in later  
12 sections of this brief, this declaration, standing alone, is sufficient to defeat ISI’s motion with  
13 respect to breach of the duty to train.

14 Under the WPLA, ISI had the same duties all manufacturers do; it can be held liable if  
15 it provided a product that was “not reasonably safe because adequate warnings or instructions  
16 were not provided.” RCW 7.72.030(1). For example,

17 A product is not reasonably safe because adequate warnings or instructions were  
18 not provided after the product was manufactured where a manufacturer learned or  
19 where a reasonably prudent manufacturer should have learned about a danger  
20 connected with the product after it was manufactured. In such a case, the  
21 manufacturer is under a duty to act with regard to issuing warnings or instructions  
concerning the danger in the manner that a reasonably prudent manufacturer would  
act in the same or similar circumstances. This duty is satisfied if the manufacturer  
exercises reasonable care to inform product users.

22 RCW 7.72.030(1)(c); *see also* RCW 7.72.030(1)(b) (describing duty of manufacturers to

23 \_\_\_\_\_  
<sup>10</sup> Helton Declaration at ¶ 7.

1 provide adequate warnings and instructions with product).

2 In his declaration, Dr. Helton addresses the fact that ISI knew or should have known  
3 that Dr. Bildsten would not be in a position to safely perform robotic prostatectomies until he  
4 had far more than the 2 proctored surgeries laid out for him by ISI in his Clinical Pathway. He  
5 then states:

6 15. For these reasons, ISI had an ethical responsibility to inform Dr. Bildsten  
7 that it would likely take him 20 to 40 procedures before he could safely perform  
8 unsupervised da Vinci prostatectomy on the average patient, and 50 procedures  
9 before he could safely perform unsupervised da Vinci prostatectomy on a patient  
10 like Fred Taylor who was not an ideal robotic surgical candidate, especially for a  
11 novice surgeon on the robot. ISI should have given these warnings to Dr.  
12 Bildsten well before they convinced him to “commit” to their “Clinical  
13 Pathway.” (These learning curve expectations should have been incorporated  
14 into the “Clinical Pathway” drafted by ISI for Dr. Bildsten.) ISI should also have  
15 given warnings of this nature to Harrison Medical Center.

16 16. Based on the clinical pathway document that ISI provided to Dr. Bildsten  
17 (PT-42), ISI suggested to Dr. Bildsten that he would be safe to operate on  
18 patients without supervision after only two proctored surgeries. Rather than  
19 telling him that the median time for even high-volume surgeons was 20 to 40  
20 procedures for basic proficiency, ISI merely told Dr. Bildsten that he might not  
21 “reach a level of comfort” until “around 20” (106-107) procedures. If indeed he  
22 was told that, such a statement would be misleading in light of the literature cited  
23 above, about which ISI, as a reasonably prudent medical device manufacturer  
knew or should have known.<sup>[11]</sup>

Dr. Helton concludes his declaration:

24 20. In light of the facts outlined above, a reasonable and responsible company in  
25 ISI’s position would have informed Dr. Bildsten and Harrison Hospital of the  
26 variable and unknown learning curve for robotic prostatectomies for any given  
27 urologist. It would not have encouraged Harrison and Dr. Bildsten to believe  
28 that Dr. Bildsten could safely operate unsupervised after having only completed  
29 its simplified training program (unapproved by the FDA) and two proctored  
30 surgeries. ISI’s actions in this regard were irresponsible and reckless.<sup>[12]</sup>

31 While there are many more facts recited below that demonstrate ISI’s breach of its duties under  
32

33 <sup>11</sup> Helton Declaration, at ¶¶ 15-16.

<sup>12</sup> Helton Declaration, at ¶ 20.

1 the WPLA to provide adequate warnings and instructions, Dr. Helton’s declaration, standing  
2 alone, is sufficient to defeat summary judgment.

3 **C. Causation**

4 As recounted by Joseph D. Schmidt, M.D., Dr. Bildsten made numerous mistakes during  
5 the Taylor surgery. According to Schmidt, it was a mistake for Bildsten to use the da Vinci at all  
6 on Mr. Taylor.<sup>13</sup> Schmidt also testified that Bildsten fell below the standard of care in failing to  
7 create a watertight anastomosis (seal) between the bladder and the urethra, once the prostate was  
8 removed.<sup>14</sup> Inflating Mr. Taylor’s abdomen with carbon dioxide pressure (“insufflation”) at 20  
9 mm for the length of time Dr. Bildsten did also fell below the standard of care.<sup>15</sup>

10 S. Adam Ramin, M.D. is a robotic surgeon who testified that Dr. Bildsten fell below the  
11 standard of care in various ways, including poor patient selection, improper insufflation, and  
12 failing to even try to obtain a water-tight anastomosis.<sup>16</sup> He testified that it is more likely than not  
13 that Mr. Taylor’s outcome would have been different if the anastomosis had been water-tight.<sup>17</sup>  
14 Among other things, he more likely than not would not have had a breakdown of the rectal repair  
15 performed as a result of Dr. Bildsten cutting Mr. Taylor’s rectum.<sup>18</sup>

16 Dr. Schmidt testified that Mr. Taylor suffered injury from the high-pressure insufflation—  
17 including encephalopathy and stroke.<sup>19</sup> Dr. Ramin testified that high-pressure insufflation can  
18 cause renal failure, decreased cardiac output, acidosis, and increased “end title CO2.”<sup>20</sup> As Dr.

19 \_\_\_\_\_  
20 <sup>13</sup> Exhibit C to Mullenix Declaration (Schmidt Deposition) at 47-48.

21 <sup>14</sup> Exhibit C to Mullenix Declaration (Schmidt Deposition) at 49 - 52.

22 <sup>15</sup> Exhibit C to Mullenix Declaration (Schmidt Deposition) at 49-50, 53.

23 <sup>16</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 102-05.

<sup>17</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 105.

<sup>18</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 105-06.

<sup>19</sup> Exhibit C to Mullenix Declaration (Schmidt Deposition) at 54-55.

<sup>20</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 108-109.

1 Ramin testified: “These are some of the problems that this patient developed,” and “the scenario  
2 here points to the intra-abdominal pressure being the main cause.”<sup>21</sup> The presence of these  
3 pressures for a very long time, as was the case in the Taylor surgery, significantly increase the  
4 chance of developing respiratory and renal complications, which Mr. Taylor suffered.<sup>22</sup>

5 These doctors and others have more to say about Dr. Bildsten’s mistakes causing injury to  
6 Mr. Taylor, but these citations are enough to establish there are genuine issues of fact in that  
7 regard.

8 Prior to this surgery, Dr. Bildsten had performed over 100 prostatectomies using the  
9 traditional “open” procedure, without a single complication.<sup>23</sup> A jury could reasonably conclude  
10 that the mistakes he made in this robotic procedure were a result of the poor training and lack of  
11 warnings he received from ISI. Indeed, that is the conclusion Dr. Bildsten has reached:

12 4. ... I was led to believe that ISI training and two proctored surgeries was  
13 sufficient to achieve basic competency and safely perform unsupervised robotic  
14 surgeries. I was not told by ISI representatives that paid expert consultants to  
15 ISI (as well as other researchers) were reporting that basic competency or  
16 proficiency were not being obtained until twenty or more operations were  
17 complete.

18 5. I relied upon ISI's representatives to give me a fair and accurate picture of  
19 ISI's training program and the learning curve.

20 6. Having learned information in FDA documents about the training program,  
21 and from other documents about research on the learning curve to obtain basic  
22 competency which I did not know at the time I became involved with ISI, I  
23 believe I likely would not have agreed to begin training on the robot had I been  
24 given this information.

25 . . . .  
26 8. At the time I committed to receiving one of Harrison Medical Center's free  
27 training slots, and thus to begin performing robotic prostatectomies, I was led to  
28 believe I would be able to provide equal or better results to my prostatectomy

29 <sup>21</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 108.

30 <sup>22</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 109.

31 <sup>23</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 42:21-43:13.

1 patients with the daVinci machine. I was not told by ISI that, especially for  
2 surgeons with no prior laparoscopic experience doing prostatectomies, this was  
3 very unlikely until I accomplished 100 or more robotic surgeries. Had I been  
4 informed of that fact, I would not have performed da Vinci surgery on Fred  
5 Taylor.

6 *9. During my robotic surgery training by ISI, I was not informed of the need  
7 to ensure a watertight urethral anastomosis. Likewise, I was not informed by  
8 ISI of the dangers of insufflating patients during long surgeries at levels over  
9 15 millimeters of mercury. Had I been so informed, I would have conducted  
10 the Taylor surgery differently, in a way that would have reduced the risk of  
11 harm to Mr. Taylor.*<sup>24</sup>

12 More facts are recited below to establish genuine issues of material fact as to whether  
13 ISI's poor training of, and lack of warnings to Dr. Bildsten was a substantial factor in causing  
14 Mr. Taylor's injuries; but the facts cited above are independently sufficient to justify denial of  
15 ISI's motion.

#### 16 **D. Damages**

17 There is no factual dispute that Mr. Taylor suffered injuries and damages during his  
18 operation. The nature and extent of the injuries is in dispute, but is not put in issue by ISI's  
19 motion. The portions of the record cited above establish not only causation, but many of the  
20 injuries.

21 Because ISI has made such an effort to convince the Court that the rectal injury did not  
22 occur during the robotic portion of the operation, plaintiff cites the court to the testimony of  
23 Dr. Ramin, which clearly refutes defendant's position:

Q Is it your opinion that it [the rectal injury] occurred during the da  
Vinci portion of the procedure before opening?

A Yes.

Q How did that happen?

A This is a portion where they were trying to again develop the

---

<sup>24</sup> Declaration of Dr. Scott Bildsten, at paragraphs 4-6, 8-9 (emphasis added).



1 Denonvillier's fascia. And based on his operative report he said after several  
2 hours of trying to develop this area, they decided to convert to open surgery.  
3 This is an area which has a high risk of cutting into the rectum and not  
4 recognizing it. The rectum is only a few millimeters away from the  
5 Denonvilliers' fascia in this particular area. And if you have more visualization,  
6 if there is blood coming into the field and bowel is coming into the field, add it to  
7 physician's fatigue, add it to a certain level of frustration, and add it to a patient  
8 not being in a correct position, it's very hard to tell whether you're properly --  
9 you are in the proper space or not. Very high chance that the rectum is injured at  
10 that point.<sup>25]</sup>

11 There are genuine issues of material fact about the damages Mr. Taylor received during  
12 surgery, and ISI cannot credibly argue otherwise.

### 13 **E. Summary**

14 The facts and law reviewed thus far are sufficient to justify denial of ISI's motion in all  
15 respects. If plaintiff was to end the brief here, however, the Court would lack context for ruling  
16 on the evidentiary motions that will shortly follow. Rather than force the Court to learn the case  
17 in a piece-meal fashion, plaintiff has elected to provide a thorough (though not complete)  
18 discussion of how the facts relate to her legal claims. It is hoped that in the long run, this will  
19 make the Court's job easier. The expanded legal arguments below should also make the Court's  
20 job easier as it considers evidentiary motions and jury instructions.

## 21 **II. STATEMENT OF FACTS**

### 22 **A. ISI is founded to pursue military-developed robotic surgery technology.**

23 In 1994, Dr. Fred Moll learned of a robotic "tele-surgery" system developed at Stanford  
24 Research Institute in California and funded by the army.<sup>26</sup> The original goal of the project was


---

25 Exhibit D to Mullenix Declaration (Ramin Deposition) at 79:10-80:3.

26 PT-240 ("Has the Real MIS Revolution Finally Arrived") at 2235.

1 to make it possible for surgeons to operate on wounded soldiers from secure locations.<sup>27</sup> Moll  
2 bought a license for the technology and founded Intuitive Surgical, Inc. (“ISI”), in 1995.<sup>28</sup> ISI’s  
3 only corporate offices in the United States are in Sunnyvale, California.<sup>29</sup> ISI also  
4 manufactures its robots in Sunnyvale.<sup>30</sup>

5 The ISI robot allows a surgeon working through a console to use to use remote-  
6 controlled instruments inside the body, as shown in the following schematic:<sup>31</sup>



14 Moll described this system in 1997 as “a new approach to minimally invasive surgery.”<sup>33</sup>

15 **B. In response to specific and explicit concern from the Food and Drug**  
16 **Administration, ISI promises to provide comprehensive training, objective**  
17 **assessment, and certification for would-be robotic surgical teams.**

18 The novelty of ISI’s surgical approach posed a hurdle in that the robot could not even  
19 be legally *advertised* in the United States when ISI began. ISI first sought permission to

20 <sup>27</sup> PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2235.

21 <sup>28</sup> PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2233 (founded ISI in 1995),  
22 2235 (licensed technology).

23 <sup>29</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 15:23-16:2. ISI’s original offices  
were in Mountain View, California. It now also maintains an office in Switzerland.

<sup>30</sup> Mullenix Declaration at ¶ 4 (Ryan Rhodes testified that robots manufactured in California).

<sup>31</sup> PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2236.

<sup>32</sup> PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2237.

<sup>33</sup> PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2233 (1997); 2236 (“new  
approach”).

1 advertise from the FDA in 1996.<sup>34</sup> The initial request sought permission only to market the  
2 device “to perform blunt dissection and to manipulate tissue, but nothing beyond that.”<sup>35</sup> In  
3 other words, ISI’s first request “included only instruments providing surgical assistance *i.e.*,  
4 retractors and graspers, rather than tools to perform surgical tasks, *i.e.*, scissors and cautery.”<sup>36</sup>  
5 However, even for these basic functions, ISI assured the FDA that it would provide *training* for  
6 surgeons who would use the device.<sup>37</sup> The draft labeling that ISI provided to the FDA stated  
7 explicitly: “Appropriate training and instructions will be provided to ensure that the surgeon is  
8 sufficiently familiar with operation of the System to be able to effectively perform the desired  
9 surgical procedures.”<sup>38</sup> The device was cleared for this limited purpose, with this  
10 understanding of “appropriate training,” on July 31, 1997.

11 Even so, by January 1999,<sup>39</sup> ISI had still not sold a single robot<sup>40</sup> or trained a single  
12 surgeon in the US.<sup>41</sup> Accordingly, ISI sought to drastically expand the manner in which it  
13 could permissibly market its robot. In pursuit of this goal, ISI filed a new application with the  
14 FDA seeking clearance to market its robot for certain kinds of laparoscopic surgical  
15 procedures: “cholecystectomy” and “Nissen fundoplication.”<sup>42</sup>

16  
17  

---

<sup>34</sup> PT-242 (K965001 Cover Sheet) at 25599.

18 <sup>35</sup> Exhibit E to Mullenix Declaration (Kreaden Transcript) at 14:9-11.

19 <sup>36</sup> PT-145 at 31447; *see also* PT-253(Indications for Use Statement for K965001) at 3167 with  
20 PT-235 (Indications for Use Statement for K990144) at 27474.

21 <sup>37</sup> PT-59 at 3137 (providing revised labeling to the FDA “to clarify our intent regarding  
22 training”).

23 <sup>38</sup> PT-59 at 3140.

<sup>39</sup> PT-241 (ISI Internal Timeline) at 27458, PT-231 (510(k) Summary) at 2706-2708.

<sup>40</sup> Exhibit E to Mullenix Declaration (Kreaden Deposition) at 72:13-17.

<sup>41</sup> Exhibit E to Mullenix Declaration (Kreaden Deposition) at 72:21-25.

<sup>42</sup> PT-231 (510(k) Summary) at 2706-2708, 2713. A cholecystectomy is a gall bladder removal  
procedure, while a Nissen fundoplication is a surgical procedure to address gastroesophageal  
reflux, or GERD.

1           ISI filed this new request under the “Premarket Notification”<sup>43</sup> regulatory regime,  
2 rather than the more burdensome and rigorous “Premarket Approval”<sup>44</sup> regulatory regime.  
3 Although there are numerous differences between these two regimes, the primary difference is  
4 that the manufacturer need demonstrate only “substantial equivalence” to a predicate device  
5 under the Premarket Notification regime, whereas the manufacturer must show “safety and  
6 efficacy” when seeking PMA Approval.<sup>45</sup> While the manufacturer makes the initial election  
7 between these regimes, the FDA can unilaterally reclassify a proposed technology into the  
8 appropriate category once it begins to review the application.

9           On May 19, 1999, the FDA did just that, reclassifying ISI’s device as a “Class III”  
10 device, meaning ISI would be required to undergo the more rigorous “PMA” process and  
11 receive “approval” for “safety and efficacy.”<sup>46</sup> On June 16, 1999, ISI presented data in support  
12 of its now-PMA application to the Medical Devices Advisory Committee of the FDA’s  
13 General and Plastic Surgery Devices Panel.<sup>47</sup> ISI’s founder, Dr. Fred Moll, personally  
14 presented information to the Panel, which asked numerous questions about the learning curve  
15 and training plan for surgeons who would use the robot. Dr. Moll assured the Panel that ISI  
16 had specific, concrete plans for training on the device:

17           I think in one sense surgeons never have enough training but, clearly, training is  
18           a very important part of this story and will be a very important part of how this  
19           system is introduced. There is no surgical device that is introduced and is

---

20 <sup>43</sup> PreMarket Notification is also sometimes referred to as the “510(k)” process, which refers to  
21 § 510(k) of the federal Food, Drug and Cosmetic Act, which is now codified at 21 C.F.R. §  
22 807.81-807.100.

23 <sup>44</sup> “PreMarket Approval” refers to § 515 of the federal Food, Drug and Cosmetic Act, which is  
now codified at 21 C.F.R. § 814.1-814.126.

<sup>45</sup> Exhibit E to Mullenix Declaration (Kreaden Deposition) at 46:19-47:2, 49:8-18.

<sup>46</sup> PT-236 at 2699; PT-55 (Panel Meeting Transcript) at 34 (“We submitted a 510(k) in January  
of this year and last month FDA made the decision to convert that 510(k) to a PMA.”).

<sup>47</sup> See PT-55.

1 immediately picked up by the surgeon and used properly without training. I  
2 won't go into specific plans about how the system, if sold in the United States,  
3 will be trained. I am probably not the right person to do that, but it is at the top of  
our mind and we will have very clear plans for introducing a training protocol  
together with the sale of this device.<sup>48]</sup>

4 Dr. Moll later added that ISI took training “very seriously,” and even regarded training as “one  
5 of the keys to both clinical and commercial success.”<sup>49</sup> The Panel advised that the robot was  
6 “approvable with conditions.”<sup>50</sup> One of the conditions was training: “The sponsor needs to  
7 provide a comprehensive training program for the users of this device.”<sup>51</sup> FDA notified ISI of  
8 the requirement on September 2, 1999.<sup>52</sup>

9 On November 26, 1999, ISI filed its proposed labeling and training program with the  
10 FDA.<sup>53</sup> The ISI employees who handled ISI’s communications with and submissions to the  
11 FDA regarding training each worked out of ISI’s California office,<sup>54</sup> and the majority of ISI’s  
12 correspondence with the FDA in general “originated in California.”<sup>55</sup>

13 In the November 1999 submission, ISI modified its earlier “indications for use” to  
14 indicate that the device was “intended for use by *trained* physicians.”<sup>56</sup> The training program  
15 that ISI described to the FDA was intense, objective, and marked by constant “expert”<sup>57</sup>  
16 assessment.<sup>58</sup> ISI stated that “consistent assessment” was one of the “key components” of its  
17 training program, a lesson purportedly learned from “the pitfalls” of the “laparoscopic boom of

---

18 <sup>48</sup> PT-55 at 78-79.

19 <sup>49</sup> PT-55 at 184.

20 <sup>50</sup> PT-100 at 26886-26887.

21 <sup>51</sup> PT-100 at 26886-26887.

22 <sup>52</sup> PT-100 at 26886-26887.

23 <sup>53</sup> PT-6.

<sup>54</sup> Exhibit E to Mullenix Declaration (Kreaden Deposition) at 34:23-35:5.

<sup>55</sup> Exhibit E to Mullenix Declaration (Kreaden Deposition) at 38:20-24.

<sup>56</sup> PT-6 at 799 (emphasis added).

<sup>57</sup> PT-6 at 815 (“Expert assessment” for Phases Two and Three).

<sup>58</sup> See PT-6 at 815.

1 the late 1980's and early 1990's."<sup>59</sup> This assessment would apply to "both cognitive and motor  
2 skills competency," and it would occur "throughout the program."<sup>60</sup> It also meant ISI would  
3 "develop and document metrics."<sup>61</sup> ISI proposed that the training would occur "in phases,"  
4 and would include "training centers."<sup>62</sup> The training centers would be required to "utilize  
5 standard performance assessment for each phase *prior to moving the learner to the next*  
6 *phase*."<sup>63</sup> ISI touted the effectiveness of its "phases" approach in its FDA submissions:

7       Each phase accomplished will build the knowledge and skills necessary to  
8       prepare the learner to successfully perform his or her role in the recommended  
9       operation of the System. Additionally, each phase will allow the instructor and  
10       learner to assess knowledge and skills *prior to moving to the next module*. This  
11       will provide for the feedback and remediation that are so important in learning  
12       new knowledge and skills. [<sup>64</sup>]

13       The first phase would be a "distance learning program"<sup>65</sup> that would "mimic the  
14       cognitive activity required during actual performance."<sup>66</sup> The program would provide the  
15       knowledge "necessary to perform pre-operative System preparations, intra-operative use and  
16       preliminary troubleshooting, and post-operative care of the System."<sup>67</sup> It would also provide "a  
17       basic understanding of computer-assisted surgery and the System."<sup>68</sup> ISI proposed to asses  
18       performance with a "70-item, multiple-choice instrument" based on "curriculum learning  
19       objectives."<sup>69</sup> The entire "surgical team" would be required to pass this test.<sup>70</sup> By the end of

---

18 <sup>59</sup> PT-6 at 814.

19 <sup>60</sup> PT-6.

20 <sup>61</sup> PT-6.

21 <sup>62</sup> PT-6.

22 <sup>63</sup> PT-6 (emphasis added).

23 <sup>64</sup> PT-6 at 815 (emphasis added).

<sup>65</sup> PT-6 at 814.

<sup>66</sup> PT-6 at 817.

<sup>67</sup> PT-6 at 814.

<sup>68</sup> PT-6.

<sup>69</sup> PT-6.

<sup>70</sup> PT-6.

1 Phase One, ISI promised, among other things, that all surgical team members would be able to  
2 “Describe patient positioning and preparation”<sup>71</sup> and all physicians would be able to “Meet  
3 team objectives” and “Identify and describe System-specific surgical skills.”<sup>72</sup>

4 The second phase was to be a “three-day, hands on program” at an “approved training  
5 center.”<sup>73</sup> Whereas the first phase was to provide knowledge, the second phase was to provide  
6 “the practical skills necessary” for pre-operative preparations, intra-operative use,  
7 troubleshooting, and post-operative care of the System.<sup>74</sup> Because the entire team would  
8 attend, the “team” would also “gain a basic understanding of team dynamics necessary for  
9 successful use of the System.”<sup>75</sup> ISI promised that “[p]erformance evaluation will be ongoing  
10 within the hands-on training throughout the course,<sup>76</sup> which would include “constructive  
11 simulation of procedures.”<sup>77</sup> Moreover: “*Expert* evaluation ... will determine mastery.”<sup>78</sup>

12 Phase Three would occur “during installation at the site of the installed System.”<sup>79</sup> The  
13 third phase would use an “installation/in-service training curriculum” to provide each of the  
14 above-mentioned skills, teach more advanced troubleshooting skills,<sup>80</sup> and further guarantee  
15 that the team gained “a basic understanding of the team dynamics necessary for successful  
16 use.”<sup>81</sup> Also, during this phase, both the “console” and “patient-side” surgeons would  
17

---

18 <sup>71</sup> PT-6 at 816.

19 <sup>72</sup> PT-6.

20 <sup>73</sup> PT-6 at 815.

21 <sup>74</sup> PT-6.

22 <sup>75</sup> PT-6.

23 <sup>76</sup> PT-6.

<sup>77</sup> PT-6 at 819.

<sup>78</sup> PT-6 at (emphasis added).

<sup>79</sup> PT-6 at 815.

<sup>80</sup> PT-6 at 815.

<sup>81</sup> PT-6 at 815.

1 “advance their surgical skills” through “intense practice on surgical models.”<sup>82</sup> ISI would also  
2 “introduce problem-solving activities during a surgical procedure.”<sup>83</sup> Again, ISI promised that  
3 “Metrics” would be developed to “certify mastery, including time and accuracy.”<sup>84</sup> Again, ISI  
4 promised that, with respect to the entire team: “Expert evaluation ... will determine mastery.”<sup>85</sup>

5 Phase Four was to be conducted by the team itself as a “self-directed” curriculum.  
6 Though this portion was self-directed, ISI still promised that trainee surgeons would “*practice*  
7 *specific procedures* on surgical models, including cadaveric models[.]”<sup>86</sup> Doing so would  
8 “result in demonstrated mastery of competence in applying surgical skills to procedural  
9 applications.”<sup>87</sup> This would occur “prior to application of the System to patients[.]”<sup>88</sup> And ISI  
10 promised to monitor the surgeons’ performance during this phase: “Monitoring of performance  
11 within the Surgeon Skills Practice to Competence phase training will be ongoing throughout  
12 the phase.”<sup>89</sup> By the end of Phase Four, ISI stated, all physicians would be able to  
13 “[d]emonstrate specific surgical skills applied to specific procedures” and even “[d]emonstrate  
14 to the Chief of Surgery the necessary competence for credentialing.”<sup>90</sup> This would be  
15 determined by “[e]xpert and peer evaluation” and “successful completion of surgical  
16 procedures.”<sup>91</sup>

17 ISI also promised, with respect to Phase Four, that that the company would provide the  
18

---

19 <sup>82</sup> PT-6 at 815.

20 <sup>83</sup> PT-6 at 821.

21 <sup>84</sup> PT-6 at 815.

22 <sup>85</sup> PT-6 at 815.

23 <sup>86</sup> PT-6 at 815 (emphasis added).

<sup>87</sup> PT-6 at 815.

<sup>88</sup> PT-6 at 815.

<sup>89</sup> PT-6 at 823.

<sup>90</sup> PT-6 at 822.

<sup>91</sup> PT-6 at 823.



1 names of “experienced preceptors and proctors” that the hospital may access if it is necessary  
2 to the credentialing process.<sup>92</sup> ISI would also provide to hospitals “a training curriculum that  
3 can be used for training” for operating room staff and surgeons.<sup>93</sup>

4 To lend credibility to the training program it proposed, ISI stated that it was partnering  
5 with an outside firm to audit and improve its training program:

6 Intuitive Surgical, Inc. is partnering with Medical Education Training Associates  
7 (META) to assess learning needs and develop and refine the curriculum in the  
8 pilot process. Additionally, META will assess the pilot program's success and  
9 design the curriculum, instructional design, and instructional delivery system for  
10 both training centers and installation sites. The META organization includes  
11 M.Ed. and Ed.D. level personnel who have had extensive experience in  
12 instructional design, simulation training, and industry sponsored device  
13 training.<sup>[94]</sup>

14 ISI included in its materials the curriculum vitae “of the principals” from META whom it  
15 proposed to work with.<sup>95</sup>

16 After reviewing ISI’s proposed training program, the FDA responded on February 2,  
17 2000, with a “Deficiency” letter.<sup>96</sup> With respect to the training program, the FDA mandated  
18 language changes, asked for definitions of terms used, and demanded that ISI provide the “tool  
19 of evaluation and criteria of success” for “each phase of the training.”<sup>97</sup> The FDA also  
20 demanded that ISI produce a copy of the “70-item multiple choice instrument” it intended to  
21 use.<sup>98</sup> The FDA required ISI to provide “additional detail” and discussion about the training

---

22 <sup>92</sup> PT-6 at 815.

23 <sup>93</sup> PT-6 at 815.

<sup>94</sup> PT-6 at 815.

<sup>95</sup> PT-6 at 815.

<sup>96</sup> PT-7 at 765.

<sup>97</sup> PT-7 at 765.

<sup>98</sup> PT-7 at 765.

1 and criteria for success in Phases Three and Four.<sup>99</sup>

2           ISI produced its response on February 22, 2000.<sup>100</sup> With respect to Phase One (the  
3 distance learning program), ISI assured that a “da Vinci™ System trainer” would perform the  
4 evaluation of trainees, and even “provide[] feedback to the surgical team.”<sup>101</sup> Likewise, a da  
5 Vinci System trainer would perform evaluations for Phases Two, Three, and Four. For Phase  
6 Three, ISI promised to “make the assessment data available to each team and the hospital  
7 official in charge of the da Vinci™ system training.”<sup>102</sup> For Phase Four, ISI promised that its  
8 trainers’ evaluations would be measured “against the [hospital] directed objectives for  
9 simulated intra-operative tasks.”<sup>103</sup> In addition to those hospital-directed objectives, the Phase  
10 Four criteria for success would be measured with “the same instruments and evaluation as  
11 Phase III training,”<sup>104</sup> “based on the surgical team's use of the da Vinci™ surgical system as  
12 applied during targeted procedure(s).”<sup>105</sup> The evaluations in Phases Two, Three, and Four,  
13 would be “quantitatively assessed ... using a Likert-type scale of one to five (1=poor and  
14 5=excellent).”<sup>106</sup>

15           On May 17, 2000, FDA sent *another* deficiency letter to ISI. This time, the FDA  
16 sought copies of the actual “distance learning materials” and “questionnaires” that ISI intended  
17 to use.<sup>107</sup> ISI responded the next day by producing its 64-page “comprehensive Training  
18  
19

---

20 <sup>99</sup> PT-7 at 765.

21 <sup>100</sup> PT-8 at 2211-2212; PT-246 at 761 (providing date).

22 <sup>101</sup> PT-8 at 2211.

23 <sup>102</sup> PT-8 at 2214.

<sup>103</sup> PT-8

<sup>104</sup> PT-8 at 2215.

<sup>105</sup> PT-8 at 2215.

<sup>106</sup> PT-8 at 2211-2212.

<sup>107</sup> PT-10 at 27497.

1 Package.”<sup>108</sup> This training package confirmed that ISI’s “Surgical Training Personnel” would  
2 be responsible for “instructional materials and facilitation” of the da Vinci training, meaning  
3 they would “Organize and facilitate” the training phases, “Assess performance” of the “da  
4 Vinci™ Surgical System gross tasks during training,” “Coordinate proctor(s) as requested,”  
5 and “Provide post training support as requested.”<sup>109</sup>

6 ISI also provided more detailed information regarding each proposed phase of its  
7 training program. For instance, ISI actually provided the 70-item test it would use to assess  
8 Phase One performance.<sup>110</sup> For Phase Two, ISI listed out 23 different goals and objectives,  
9 promising to train on 22 of those goals during the three-day off-site training.<sup>111</sup> Relevant to  
10 this case, that training was to include: (a) “Patient Positioning and Preparation,”<sup>112</sup> which  
11 would require the trainee to “Describe and demonstrate patient position on table matching OR  
12 procedure,”<sup>113</sup> (b) “Secondary troubleshooting,”<sup>114</sup> which addressed “Insufflator device  
13 operation and settings”<sup>115</sup> and required trainees to recognize when the “Position of Position of  
14 patient on [the] table [was] incorrect for da Vinci Surgical System procedure,”<sup>116</sup> (c) “Surgical  
15 skills”, which required the surgeon to “Identify, perform, and evaluate the specific surgical  
16  
17

18 \_\_\_\_\_  
<sup>108</sup> PT-10 at 27548-27614; PT-10 at 27497 (“comprehensive Training Package”).

19 <sup>109</sup> PT-10 at 27549.

20 <sup>110</sup> PT-10 at 27554-27569.

21 <sup>111</sup> PT-10 at 27572 (day one), 27574 (day two), 27580 (day three). “Anesthesia considerations”  
was the only goal that ISI did not explicitly promise to train upon in Phase Two. As noted  
below, ISI did promise to train on anesthesia considerations in Phase Three. PT-10 at 27591.

22 <sup>112</sup> PT-10

<sup>113</sup> PT-10 at 27605.

23 <sup>114</sup> PT-10 at 27574.

<sup>115</sup> PT-10 at 27609.

<sup>116</sup> PT-10 at 27609.

1 skills utilized during surgery using the da Vinci Surgical System and a training model,”<sup>117</sup> (d)  
2 “Interference of Arms, instruments, scopes, masters, and patient anatomy,” which would  
3 address “body positioning (patient and table)”<sup>118</sup> with the surgeon; and (e) “Team Dynamics,”  
4 which would require the entire team to be able to “Describe roles and responsibilities of  
5 individual team members, pre-procedure, intraoperatively, and post-procedure.”<sup>119</sup> Each of  
6 these skills would be rated, from 1-5 (1 = Beginner, 5 = Expert), by the trainer.<sup>120</sup>

7 ISI also provided a 13-page agenda that would be used for the training.<sup>121</sup> Among the  
8 agenda items relevant to this case:

- 9 • A Day 2 lunchtime review of a “Pre-test.”
- 10 • 3 tasks related to Patient Positioning and Preparation, including:  
11 “Describe and demonstrate patient position on table *matching sample OR*  
*procedure.*”
- 12 • A two hour and 45 minute session for the entire surgical team in the  
13 “Cadaver or Animal Lab” for “LAP CHOLE AND/OR NISSEN”. This includes  
14 a section called “Lap Chole or Lap Nissen Procedure,” which included:  
15 “Identify, demonstrate and evaluate Surgical Skills.” The lab session was  
16 followed by a 45 minute “SURGEON’S Review” session. That review session  
17 included a “Surgeon’s Self Assessment of Surgical Skills.”<sup>122</sup>
- 18 • Day 3 included, for the entire team, a one hour and 15 minute “Dry Lab”  
19 session plus four more hours in the “Animal or Cadaver Lab.” That session  
20 would include more drilling on patient positioning and preparation and, among  
21 other things, another “Lap Chole or Lap Nissen.”<sup>123</sup> The lab session was to be  
22 followed by another 45 minute Surgeon’s Review, and another “Self Assessment  
23

---

18 <sup>117</sup> PT-10 at 27612-27613. These skills included: “Dissection – blunt/sharp; Tissue handling;  
19 Ligating; Holding/passing needles; Suturing skills - large and fine; Knot tying - tensioning large  
20 and fine’ Ambidexterity; Vision - Anatomy identification within field of view/focal length.  
21 Identify skill performance differences with 2-D vs. 3-D. Perform and demonstrate non-dominate  
22 [sic] hand skills.” *Id.*

21 <sup>118</sup> PT-10 at 27614.

22 <sup>119</sup> PT-10 at 27614.

23 <sup>120</sup> PT-10 at 27572 (day one), 27574 (day two), 27580 (day three).

<sup>121</sup> PT-10 at 27572-27585.

<sup>122</sup> PT-10 at 27579.

<sup>123</sup> PT-10 at 27583.

1 of Surgical Skills.”<sup>124</sup>

2 Finally, during the lunch break on the third day of the offsite training, the surgical team and  
3 expert trainers would “Create On-Site Plan/Agenda for Installation (Phase 3).”<sup>125</sup> At the end of  
4 that day, ISI assured, the entire surgical team would review its “Workshop Assessment and  
5 recommendations for On-Site training.”<sup>126</sup>

6 In supplementing Phase Three, ISI explained that Phase Three would be the  
7 implementation of the On-Site Plan created as a result of the training and assessment done  
8 during Phase Two.<sup>127</sup> The Phase Three training agenda is similar to, but more detailed, than the  
9 Phase Two agenda. Again, ISI would train on the same list of 23 Goals and Objectives.  
10 Again, ISI would “Rate Team’s Proficiency” from 1-5 (1 = Beginner, 5 = Expert).<sup>128</sup> ISI also  
11 provided a seven page list of specific tasks, correlated to the list of goals, that the trainees  
12 would be required to perform in order to earn their rating. For instance, the table that  
13 corresponds with Goal #5 (Patient Positioning and Preparation) requires the nurses and  
14 surgeons to “Describe and demonstrate patient position on table matching sample O.R.  
15 Procedure.”<sup>129</sup>

16 Unlike the Phase Two agenda, the Phase Three agenda also included a section on  
17 “Anesthesia Considerations.”<sup>130</sup> This portion of the Phase Three curriculum would require  
18

---

19 <sup>124</sup> PT-10 at 27585.

20 <sup>125</sup> PT-10 at 27585.

21 <sup>126</sup> PT-10 at 27585.

22 <sup>127</sup> PT-10 at 27588 (“This On-Site/Installation Plan is customized for each institution. It is  
derived from Instructor Assessments of the surgical team at the end of Phase 2 and from a needs  
assessment identified by the surgical team and Project Manager.”).

23 <sup>128</sup> PT-10 at 27589.

<sup>129</sup> PT-10 at 27591.

<sup>130</sup> PT-10 at 27589.

1 participation by the anesthesiologist, nurses, clinical technician, and surgeons.<sup>131</sup> It would  
2 require each of these participants to, in various ways: “Explain importance of patient  
3 positioning.”<sup>132</sup> Also unlike Phase Two, Phase Three included a “Dry Run of Procedure with  
4 Training Model.”<sup>133</sup> The dry run would include a section on the “Interference of ... Patient  
5 Anatomy,” which includes demonstration of “Body positioning (patient and table).”<sup>134</sup>

6 Finally, ISI provided further detail on Phase Four, which it described again as “Surgeon  
7 Directed Training.”<sup>135</sup> ISI explained that Phase Four would address “basic and advanced  
8 minimally invasive skills applied to the da Vinci™ Surgical System.”<sup>136</sup> The surgeon, ISI  
9 assured, would “identify, perform, and evaluate the specific surgical skills utilized during  
10 surgery using the da Vinci™ Surgical System and a training model.”<sup>137</sup> The surgeon would  
11 have “sufficient information to objectively assess and document the results” of this further  
12 training due to the “Didactic and practical experiences” conducted during Phase Two.<sup>138</sup>  
13 Moreover, ISI promised, the surgeons would complete a “self assessment ... at the completion  
14 of Phase Two and/or Phase Three.”<sup>139</sup>

15 ISI even provided the forms that it would use for this self-assessment.<sup>140</sup> These forms  
16 required assessment of the “surgical skills used during surgery with the da Vinci Surgical  
17 System.” This included assessment of the surgeon’s mastery of the “Principles of  
18

---

19 <sup>131</sup> PT-10 at 27591.

20 <sup>132</sup> PT-10 at 27591.

21 <sup>133</sup> PT-10 at 27593-27594.

22 <sup>134</sup> PT-10 at 27593-27594.

23 <sup>135</sup> PT-10 at 27597-27960.

<sup>136</sup> PT-10 at 27597.

<sup>137</sup> PT-10 at 27597.

<sup>138</sup> PT-10 at 27597.

<sup>139</sup> PT-10 at 27597.

<sup>140</sup> PT-10 at 27599-27600.

1 insufflation.” The forms also required assessment of the surgeons’ ability to perform the  
2 procedures themselves: i.e., the surgeon would be asked to rate whether they were “able to  
3 perform and demonstrate understanding of ... Minimally Invasive Cholecystectomy using the  
4 da Vinci™ Surgical System.”<sup>141</sup> Likewise, a surgeon receiving training on Nissen  
5 Fundoplication would rate, after Phase Two and/or Phase Three, the surgeon’s ability “to  
6 perform ... Minimally Invasive Nissen Fundoplication” with the da Vinci Surgical System.<sup>142</sup>

7 In summary, ISI promised the FDA a “comprehensive”<sup>143</sup> training program marked by  
8 “consistent”<sup>144</sup> assessment performed by “experts” using documented and specifically  
9 developed “metrics.”<sup>145</sup> Phase One would be distance education followed by a 70-question<sup>146</sup>  
10 exam, specific “feedback”<sup>147</sup> from an “instructor,”<sup>148</sup> and “remediation.”<sup>149</sup> Phase Two would  
11 be a three-day,<sup>150</sup> whole team,<sup>151</sup> hands-on<sup>152</sup> training course that would teach the trainees  
12 specific patient and table positions for specific procedures,<sup>153</sup> address insufflator settings,<sup>154</sup>  
13 and require the surgeons to perform the specific surgical skills<sup>155</sup> for a given surgery. 22 of 23  
14 skillsets<sup>156</sup> would be taught, and each of those skillsets would be assessed with a Likert  
15

---

16 <sup>141</sup> PT-10 at 27599.

17 <sup>142</sup> PT-10 at 27600.

18 <sup>143</sup> PT-10 at 27497.

19 <sup>144</sup> PT-6 at 814.

20 <sup>145</sup> PT-6 at 814, 815.

21 <sup>146</sup> PT-6 at 814; PT-10 at 27554-27569.

22 <sup>147</sup> PT-6 at 815.

23 <sup>148</sup> PT-6 at 815.

<sup>149</sup> PT-6 at 815.

<sup>150</sup> PT-6 at 815.

<sup>151</sup> PT-6 at 815.

<sup>152</sup> PT-6 at 815.

<sup>153</sup> PT-10 at 27605, 27609.

<sup>154</sup> PT-10 at 27609.

<sup>155</sup> PT-10 at 27612-27613.

<sup>156</sup> PT-10 at 27572 (day one), 27574 (day two), 27580 (day three).

1 rating.<sup>157</sup> This practical experience would also be sufficient<sup>158</sup> to allow for the surgeon to self-  
2 assess,<sup>159</sup> at that time, his or her ability to perform the given procedures<sup>160</sup> on humans with the  
3 da Vinci robot. The entire surgical team would then work with the expert trainers to create a  
4 plan<sup>161</sup> for the next phase: implementation. Phase Three implementation would require the  
5 console and patient-side surgeons to advance their surgical skills through “intense practice”<sup>162</sup>  
6 on “specific procedures”<sup>163</sup> using “cadaveric models.”<sup>164</sup> Their performance would be  
7 compared by ISI against objective metrics and certified for mastery.<sup>165</sup> ISI would also make  
8 this assessment data available to the team and the hospital.<sup>166</sup> Phase Three would also require  
9 the surgical team to incorporate and educate an anesthesiologist<sup>167</sup> before conducting a “dry  
10 run.”<sup>168</sup> Phase Four would ensure the surgeon had “sufficient information to objectively  
11 assess”<sup>169</sup> his or her readiness to perform actual, specific procedures: cholecystectomy and  
12 Nissen Fundoplication. And ISI promised to “partner”<sup>170</sup> with META to take advantage of  
13 META’s “M.Ed. and Ed.D. level personnel”<sup>171</sup> as ISI and META further developed and  
14 assessed “the curriculum, instructional design, and instructional delivery system for both  
15

---

16 <sup>157</sup> PT-8 at 2211-2212.

17 <sup>158</sup> PT-10 at 27597.

18 <sup>159</sup> PT-10 at 27599-27600.

19 <sup>160</sup> PT-10 at 27599 (cholecystectomy), 27600 (Nissen fundoplication).

20 <sup>161</sup> PT-10 at 27588.

21 <sup>162</sup> PT-6 at 815.

22 <sup>163</sup> PT-6 at 815.

23 <sup>164</sup> PT-6 at 815.

<sup>165</sup> PT-6 at 815.

<sup>166</sup> PT-8 at 2214.

<sup>167</sup> PT-10 at 27591.

<sup>168</sup> PT-10 at 27593-27594.

<sup>169</sup> PT-10 at 27597.

<sup>170</sup> PT-6 at 815.

<sup>171</sup> PT-6 at 815.



1 training centers and installation sites.”<sup>172</sup> All of this was designed to ensure “demonstrated  
2 mastery of competence in applying surgical skills to procedural applications”<sup>173</sup> *before*  
3 surgeons operated unsupervised on live human beings.

4 **C. Having received assurances regarding the proposed training, the FDA  
5 reclassifies and clears ISI’s device for marketing of specific procedures.**

6 Shortly after receiving ISI’s “comprehensive Training Package,” the FDA again  
7 reclassified ISI’s application, switching back to the less rigorous Premarket Notification  
8 process.<sup>174</sup> Importantly, this regulatory change from Premarket Approval to Premarket  
9 Notification did not modify the application so far as it concerned ISI’s promises regarding  
10 training of surgical teams. ISI thus admits that “the material that had been submitted prior to  
11 clearance, even if it was under a PMA designation,” remained “part of the ... file.”<sup>175</sup> As  
12 explained by Suzanne Parisian, M.D. – a former FDA Medical Officer and instructor at the  
13 FDA’s “staff college” – ISI was *required* to provide no less than the rigorous training program  
14 described in its submissions:

15 [I]t's their responsibility, introducing a new technology, to ensure that the  
16 physicians who are using it have adequate training and experience and  
17 knowledge before you allow them just to go off with a new device. And they  
18 took it upon themselves when they got the 510(k) clearance . . . . The company  
19 agreed voluntarily that they were going to do this, that it was a commitment.<sup>176</sup>

20 In fact, Parisian explained, the only way a product like da Vinci *could* have been cleared via  
21 Premarket Notification was with a commitment for “adequate physician training.”<sup>177</sup>

---

22 <sup>172</sup> PT-6 at 815.

23 <sup>173</sup> PT-6 at 815.

<sup>174</sup> PT-135 at 31448.

<sup>175</sup> Exhibit E to Mullenix Declaration (Kreaden Deposition) at 75:25-76:6.

<sup>176</sup> Exhibit F to Mullenix Declaration (Parisian Deposition) at 25:15-25.

<sup>177</sup> Exhibit F to Mullenix Declaration (Parisian Deposition) at 25:25-26:11 (“to make it  
equivalent, they have to make sure the physicians are trained to be able to use the product.”).

1 In its Supplemental Brief, ISI asserts that “the FDA did not impose a training  
2 requirement on Intuitive” before Intuitive was permitted to market the da Vinci Surgical  
3 System.<sup>178</sup> But even ISI’s Chief Medical Officer, Dr. Curet, a CR 30(b)(6) designee,  
4 recognized the absurdity of the notion that *no* training was required by the FDA:

5 if the FDA came and asked, we'd be required to prove to them that [ISI’s training  
6 program] was adequate. So I think it's -- we can't just make a decision because  
7 it's easy for us, right? We have to make a decision that would satisfy that the  
8 FDA would agree that it was training them -- training the user safely on it.<sup>[179]</sup>

9 Indeed, Dr. Curet has gone further, having published an article stating that ISI’s  
10 training program was *mandated* by the FDA.<sup>180</sup>

11 Ultimately, on July 11, 2000, the FDA cleared the device for marketing of the two  
12 laparoscopic procedures, laparoscopic Cholecystectomy and Nissen Fundoplication, in the  
13 United States.<sup>181</sup> In an application filed the next month,<sup>182</sup> ISI also sought clearance to  
14 advertise its robot for “general non-cardiovascular thoracoscopic procedures such as internal  
15 mammary artery mobilization.”<sup>183</sup> ISI’s application materials for thoracoscopic procedures  
16 contained a materially identical training proposal.<sup>184</sup> The FDA cleared that device for

---

17 <sup>178</sup> Defendant Intuitive Surgical, Inc.’s Supplemental Brief in Support of Its Motion for  
18 Summary Judgment on All Claims and for Partial Summary Judgment on Plaintiffs’ Claim for  
19 Punitive Damages, at 2. The parties’ dispute regarding whether the FDA mandated training is  
20 not essential to resolution of this motion. The important point about ISI’s extensive  
21 representations to the FDA about the type of training it would provide is that they represents  
22 ISI’s own description of what it considered an appropriate training program, which contrasts  
23 starkly with the training it later provided.

<sup>179</sup> Exhibit G to Mullenix Declaration (Curet Deposition) at 47:13-18.

<sup>180</sup> See PT-68 at ¶ (I)

<sup>181</sup> PT-235 (July 11, 2000, clearance letter) at 27472-27474.

<sup>182</sup> See [http://www.accessdata.fda.gov/cdrh\\_docs/pdf/k002489.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf/k002489.pdf) (accessed Jan. 3, 2013)  
(stating application for K002489 was prepared August 8, 2000).

<sup>183</sup> PT-239 (Clearance Letter for K002489) at 12314-12315.

<sup>184</sup> PT-11 at 10056-10103.

1 marketing, via the Pre-Market Notification process, on March 2, 2001.<sup>185</sup>

2 At this point, however, ISI was still not allowed to market its robot in the United States  
3 for laparoscopic radical prostatectomy, the procedure Fred Taylor ultimately underwent in  
4 September 2008. Rather, as an ISI CR 30(b)(6) designee testified, ISI was required to submit a  
5 new pre-market notification to the FDA “every time [ISI] want[ed] to market a procedure in a  
6 new surgical specialty for which it doesn't already have clearance.”<sup>186</sup>

7 **D. ISI is caught by the FDA improperly marketing its device for prostatectomy.**

8 Although it had not received clearance to market its robot for laparoscopic radical  
9 prostatectomy or cardiac procedures, ISI began to do so illegally in early 2001.<sup>187</sup> On February  
10 20, 2011,<sup>188</sup> and again on and April 12, 2001,<sup>189</sup> the FDA sent “Warning” letters to ISI about its  
11 illegal “off-label” advertising. Specifically, the FDA informed ISI that its “promotion of the  
12 device for off-label uses such as prostatectomies and cardiac procedures misbrands and  
13 adulterates the da Vinci™ system,” and ordered ISI to take “prompt action to correct these  
14 violations.”<sup>190</sup>

15 **E. ISI seeks FDA approval for prostatectomy, claiming “substantial equivalence”  
16 with its own prior FDA submissions, which included detailed training  
programs.**

17 In response to these letters, ISI submitted a Pre-Market Notification application for  
18 clearance to advertise for laparoscopic prostatectomy.<sup>191</sup> ISI claimed “substantial equivalence”  
19

---

20 <sup>185</sup> See [http://www.accessdata.fda.gov/cdrh\\_docs/pdf/k002489.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf/k002489.pdf) (accessed Jan. 3, 2013)  
(stating decision of substantial equivalency made March 2, 2001).

21 <sup>186</sup> Exhibit E to Mullenix Declaration (Kreaden Deposition) at 89:4-6.

22 <sup>187</sup> PT-136.

23 <sup>188</sup> PT-136.

<sup>189</sup> PT-27 at 1.

<sup>190</sup> PT-27 at 3.

<sup>191</sup> PT-92.

1 with the three indications the FDA had earlier cleared: blunt dissection (K965001),  
2 laparoscopic cholecystectomy and Nissen fundoplication (K990144), and internal mammary  
3 artery mobilization (K002489).<sup>192</sup> ISI's robotic prostatectomy application did not indicate that  
4 it intended to modify the earlier, cleared iterations of its training programs. Rather, it  
5 submitted an indication that stated, like the earlier indications, that its robot was "intended to  
6 be used by trained physicians in an operating room environment."<sup>193</sup> ISI's Vice President of  
7 Clinical, Regulatory, and Quality Affairs certified to the FDA that "no material fact has been  
8 omitted" from the "data and information submitted in this pre-market notification."<sup>194</sup>

9 **F. ISI's Gene Nagel drastically reduces the rigor of the training and assessment**  
10 **program under the guise of making the program more "efficient."**

11 In November 2000, only four months after receiving its first surgical clearance, ISI  
12 hired Gene Nagel to take over (among other things) its surgeon training program. Nagel was  
13 not a physician or an educator. His college degree was in marketing and operations  
14 management.<sup>195</sup> After college, he had spent thirteen years as a salesman, first on behalf of two  
15 wineries, and then at a medical device company.<sup>196</sup> He then spent two years as a manager at the  
16 device company, "teaching the salespeople how to sell."<sup>197</sup> When he joined ISI in 2000, he had  
17 never had any higher education in the fields of education<sup>198</sup> or "medical related subjects."<sup>199</sup>

18 Despite his lack of relevant experience or education, in July 2001, ISI put Nagel in  
19

---

20 <sup>192</sup> PT-92.

21 <sup>193</sup> PT-92.

22 <sup>194</sup> PT-92 at 3247.

23 <sup>195</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 10:1-11:1; 22:10-18.

<sup>196</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 10:1-11:1; 22:10-18.

<sup>197</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 11:2-10; 11:15-17.

<sup>198</sup> See Exhibit B to Mullenix Declaration (Nagel Deposition) at 10:5-6.

<sup>199</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 19:12-15.

1 charge of its *surgeon* training program.<sup>200</sup> Moreover, ISI allowed Nagel to make substantial  
2 changes to the surgeon training program without approval from anyone else at ISI.<sup>201</sup> ISI  
3 likewise chose not to partner with META to guide Nagel, despite its promise to the FDA to  
4 partner with META “to assess learning needs and develop and refine the curriculum” for the  
5 promised surgeon training. Nor did META “assess the pilot program's success and design the  
6 curriculum, instructional design, and instructional delivery system for both training centers and  
7 installation sites,”<sup>202</sup> as ISI had said it would. Rather, ISI’s only contract with META  
8 concerned the training of ISI’s *sales force* in how to best sell ISI’s robot.<sup>203</sup>

9 Without META’s guidance, and under Nagel’s unqualified and unchecked direction,  
10 ISI drastically reduced the rigor and quality of the training program it had promised the FDA.  
11 Nagel testified that he did so because the existing training program was being done  
12 “inefficiently in terms of down time.”<sup>204</sup> Specifically, the post-Nagel training program was not  
13 “comprehensive,” was not marked by “consistent” assessments, was not conducted by  
14 “experts,” and was not conducted using developed “metrics.”<sup>205</sup> In fact, ISI never required that  
15

---

16 <sup>200</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 8:15 (“customer training”); 18:11-  
17 23 (took over customer training in approximately July 2001).

17 <sup>201</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 92:6-10.

18 <sup>202</sup> PT-6 at 815. ISI’s failure to work, as promised, with META, is particularly dumbfounding  
19 given that Nagel had actually worked with Nagel at the device company he left to join ISI.  
20 Exhibit B to Mullenix Declaration (Nagel Deposition) at 117:11-15.

19 <sup>203</sup> PT-244 (META Letter) at 31583-31584.

20 <sup>204</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 81:4; *see generally* Exhibit B to  
21 Mullenix Declaration (Nagel Deposition) at 79:24-85:7. In retrospect, it makes sense that Mr.  
22 Nagel cared so much about making the surgeon training program as short as possible. Damon  
23 Daniels, the ISI salesman who convinced Dr. Bildsten to “commit” to robotic surgery, testified  
that the “most common” objection he encountered from surgeons he sought to train was “time.”  
Exhibit A to Mullenix Declaration (Daniels Deposition) at 272:11-17. Specifically, surgeons  
would say: “I don't have time to take away from my practice, I don't have time to train, I don't  
have time to come and spend time with you at the console and practice, time, period.” *Id.*

<sup>205</sup> Exhibit H to Mullenix Declaration (Lederer Deposition) at 77:24-78:2.

1 its “expert” trainers have any prior education in medicine or teaching.<sup>206</sup>

2 With respect to Phase One, ISI did not, under Nagel, provide a 70-question exam  
3 followed by specific “feedback” and remediation from an “instructor.” Rather, the entirety of  
4 Phase One, which was developed and revised in California,<sup>207</sup> was simply a video that was less  
5 than one hour long and a ten question quiz.<sup>208</sup> Moreover, this quiz was impossible to fail  
6 because, when a trainee selected an incorrect answer, the online program would simply prompt  
7 the trainee to choose a different answer.<sup>209</sup> When the trainee finally selected the correct answer,  
8 only that correct answer would be recorded in the test taker’s final score.<sup>210</sup> For this reason,  
9 *every test-taker receives a perfect score at the end of the exam.*<sup>211</sup> ISI had promised a distance  
10 learning program that would “mimic the cognitive activity required during actual performance”  
11 and ensure that all trainee surgeons could “[i]dentify and describe System-specific surgical  
12 skills.” The program Nagel actually delivered for this phase was, in his words, a “very cursory  
13 basic overview of the system.”<sup>212</sup>

14  
15  
16 <sup>206</sup> Exhibit H to Mullenix Declaration (Lederer Deposition) at 16:19-17:3, 51:10-14; Exhibit B  
to Mullenix Declaration (Nagel Deposition) at 94:12-15.

17 <sup>207</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 65:12-15.

18 <sup>208</sup> PT-5A at 31309-31321; Exhibit B to Mullenix Declaration (Nagel Deposition) at 87:9-11  
 (“I’m the one who -- who made the decision to convert it to an online module with a ten-  
question test.”).

19 <sup>209</sup> See, PT-5A at 31309 (“Incorrect – Please Try Again”); PT-5 at 40:00-42:43 (“Your Score:  
100; Max Score: 100”); Exhibit B to Mullenix Declaration (Nagel Deposition) at 63:5-15,  
64:18-21 (“Q. But in this phase, there's no way to fail this test, is there, unless you have a heart  
20 attack in the middle or something? A. I don't know.”).

21 <sup>210</sup> See, PT-5A at 31309 (“Incorrect – Please Try Again”); PT-5 at 40:00-42:43 (“Your Score:  
100; Max Score: 100”); Exhibit B to Mullenix Declaration (Nagel Deposition) at 63:5-15,  
64:18-21 (“Q. But in this phase, there's no way to fail this test, is there, unless you have a heart  
22 attack in the middle or something? A. I don't know.”).

23 <sup>211</sup> See Exhibit B to Mullenix Declaration (Nagel Deposition) at 65:9-10 (“Q. Are you aware of  
anybody ever failing this test? A. I'm not.”).

<sup>212</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 64:4.

1 Nagel reduced Phase Two from the promised three days down to one.<sup>213</sup> He also  
2 eliminated participation of the whole team as promised, limiting Phase Two just to the  
3 surgeons.<sup>214</sup> Phase two also did not include the promised training on insufflator settings<sup>215</sup> or  
4 require the surgeons to perform the specific surgical skills for a given surgery.<sup>216</sup> In fact, at the  
5 relevant time, only pigs (not cadavers) were used to train the surgeons trying to learn da Vinci  
6 prostatectomy,<sup>217</sup> and pigs do not even have prostates.<sup>218</sup> This revised Phase Two was  
7 finalized in California.<sup>219</sup>

8 Likewise, and contrary to ISI's promises, no Likert ratings were used in Nagel's Phase  
9 Two. In fact, no written forms are used at all.<sup>220</sup> Surgeons were not asked to self-assess, let  
10 alone given sufficient information to rate their own performance on a specific procedure.<sup>221</sup> In  
11 fact, the trainers would often be training two surgeons at the same time, meaning the trainers  
12 could watch only *half* of the activities they were supposedly assessing and correcting.<sup>222</sup>

13 At the end of Phase Two, there was no implementation plan created through the joint  
14 work of expert trainers and the entire surgical team so as to address specific skills or  
15 knowledge deficiencies. (In fact, there were no "expert" trainers.) Thus, that plan did not  
16

---

17 <sup>213</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 88:13-89:7, 90:16-90:21; 99:7-8.

18 <sup>214</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 100:6-100:23.

19 <sup>215</sup> PT-10 at 27609; Exhibit B to Mullenix Declaration (Nagel Deposition) at 47:14-15.

20 <sup>216</sup> Exhibit H to Mullenix Declaration (Lederer Deposition) at 45:5-10 ("As it relates to urology  
is nonspecific."); Exhibit G to Mullenix Declaration (Curet Deposition) at 63:16-19 ("Q. As I  
am understanding what you're saying, you're saying ISI does not train on how to do procedures,  
including robotic prostatectomy. A. That's correct."); at 76:14-15 ("We aren't in the position to  
teach somebody how to do a procedure.").

21 <sup>217</sup> Exhibit H to Mullenix Declaration (Lederer Deposition) at 81:18-20.

22 <sup>218</sup> PT-243 (Lieberman Article Excerpt) at 18 ("pigs have no fat or prostate gland").

23 <sup>219</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 67:18-67:6.

<sup>220</sup> Exhibit H to Mullenix Declaration (Lederer Deposition) at 77:24-78:2.

<sup>221</sup> Exhibit G to Mullenix Declaration (Curet Deposition) at 100:2-101:1.

<sup>222</sup> Exhibit H to Mullenix Declaration (Lederer Deposition) at 40:1-7.

1 serve as a basis for any Phase Three work. In fact, there was no “standard performance  
2 assessment” for *any* phase.<sup>223</sup> Nagel decided to stop conducting performance assessments and  
3 self-assessments in approximately 2002.<sup>224</sup>

4 Likewise, Nagel’s Phase Three did not require that surgeons advance their surgical  
5 skills through “intense practice” on “specific procedures” using “cadaveric models.”<sup>225</sup> Rather,  
6 ISI’s actual Phase Three consisted of a 45 minute “dry run” procedure that took place, without  
7 an anesthesiologist, the night before the first surgery on a live human.<sup>226</sup> ISI thus did not  
8 compare that performance against objective metrics or certify the surgeons for mastery.<sup>227</sup> Nor  
9 could ISI make any such assessment data available to the team or hospital.

10 Phase Four under Nagel was essentially non-existent. ISI does offer to find proctors for  
11 trainee surgeons and hospitals, for a fee,<sup>228</sup> but it refused to vouch for the experience of those  
12 proctors.<sup>229</sup> As noted for Phase Two, ISI did not ensure the surgeon had “sufficient  
13 information to objectively assess” his or her readiness to perform actual, specific procedures.  
14 In the absence of those assessments and remediation, Phase Four now consists solely of  
15

---

16 <sup>223</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 76:24-77:1.

17 <sup>224</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 79:21-23, 81:8-18.

18 <sup>225</sup> See Exhibit I to Mullenix Declaration (O’Connor Deposition) at 53:23-54:9, 54:11-12.

19 <sup>226</sup> Exhibit I to Mullenix Declaration (O’Connor Deposition) at 54:11-12 (training between  
offsite training and first cases consists of 45 minute dry run the night before the first case);  
20 Exhibit B to Mullenix Declaration (Nagel Deposition) at 74:4-5.

21 <sup>227</sup> Exhibit I to Mullenix Declaration (O’Connor Deposition) at 56:2-10 (no written evaluations  
or testing after Phase Two training).

22 <sup>228</sup> Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 54:22-55:1 (ISI told proctors how  
much to charge); 59:2-60:4 (ISI charged hospitals \$3,000 for proctoring, \$2,000 of which would  
go to the proctor, and \$1,000 of which would go to ISI to reimburse proctor for travel expenses;  
ISI would reimburse surgeon only for travel expenses incurred, keeping the remainder).

23 <sup>229</sup> PT-256 at 25 (“Intuitive does not express or imply that a given proctor on the list satisfies  
any credentialing requirement of the User.... all Proctors listed or referred by Intuitive are  
independent contractors.”).



1 “advanced training and case observation.”<sup>230</sup> And as later illustrated by Dr. Bildsten’s  
2 experience, the “advanced training” that ISI offered to surgeons would *not* be provided the  
3 surgeons *before* their first live patient.<sup>231</sup> “Advanced training” was offered only to surgeons  
4 who had already “done an initial series of cases”<sup>232</sup> on live human beings.

5 A description of the training process to a surgeon by ISI in July 2008 shows the truly  
6 abbreviated nature of the surgeon training program implemented under Nagel. That  
7 description describes an “online orientation module” that the surgeon could expect to take “1  
8 hour,” an “onsite inservice” that the surgeon could expect to take “4 hours,” offsite training on  
9 the “porcine model” in California (seven hours), and a “dry run first case” a “day or two prior  
10 to first case.”<sup>233</sup>

11 To summarize, even as ISI sought clearance from the FDA to market for prostatectomy,  
12 Nagel was reducing ISI’s surgeon training program without review by any medically trained  
13 person. ISI did this notwithstanding its claim that its prostatectomy submission was  
14 “substantially equivalent” to the two prior premarket notifications, each of which documented  
15 a rigorous training program. Moreover, ISI has never notified the FDA of any “changes that  
16 were made to that training protocol.”<sup>234</sup> In the words of ISI’s former director of clinical and  
17 regulatory affairs: “we did not believe it was necessary to inform FDA with every little change  
18 that was made to a training program.”<sup>235</sup>

---

21 <sup>230</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 75:9-13.

22 <sup>231</sup> Exhibit B to Mullenix Declaration (Daniels Deposition) at 250:3-25.

23 <sup>232</sup> Exhibit B to Mullenix Declaration (Daniels Deposition) at 250:3-25.

<sup>233</sup> PT-238 (Carson Email of July 1, 2008) at 32425.

<sup>234</sup> Exhibit E to Mullenix Declaration (Kreaden Deposition) at 42:2-4, 66:21-67:5.

<sup>235</sup> Exhibit E to Mullenix Declaration (Kreaden Deposition) at 58:10-12.

1       **G. While the training program that ISI promised the FDA was arguably**  
2       **reasonable, the training program ISI has actually implemented is**  
3       **unreasonable.**

4           Notably, no urologist has ever failed ISI's "certification" course.<sup>236</sup> Nor is there any  
5       indication that any other surgeon has failed any of the other phases of ISI's training  
6       program.<sup>237</sup> At trial, the plaintiff will present the testimony of William Helton, M.D. with  
7       respect to the reasonableness of the various iterations of ISI's surgeon training programs. Dr.  
8       Helton was one of the first general surgeons in America to use ISI's robot, and he also led one  
9       of the largest clinical and robotic surgery training programs in America in the early 2000s.<sup>238</sup>  
10      Dr. Helton has analyzed the material ISI presented to the FDA<sup>239</sup> and the evidence showing the  
11      actual training program ISI provided to surgeons when it trained and certified Dr. Bildsten.<sup>240</sup>

12           Dr. Helton concludes that ISI's initially proposed training program "could have been,"  
13      with certain caveats,<sup>241</sup> "a reasonable introductory training regime for training surgeons on the  
14      use of the da Vinci system in surgery."<sup>242</sup> However, especially after the Nagel changes, that  
15      training program was unreasonably unsafe:

16           7. The actual training program, in use at the time of Dr. Bilstein's training,  
17      described by Nagel and Lederer lacks depth and breadth, is incomplete, and is  
18      potentially unsafe. There was no logical reason or rationale to scale back the

19      

---

<sup>236</sup> Exhibit H to Mullenix Declaration (Lederer Deposition) at 51:21-24.

20      <sup>237</sup> Exhibit I to Mullenix Declaration (O'Connor Deposition) at 111:6-14 ("Has any surgeon ever  
21      failed the online training? A. Not to my knowledge. Q. To your knowledge, has any surgeon  
22      ever failed the on-site training? A. Not to my knowledge. Q. To your knowledge, has any  
23      surgeon ever failed the off-site training? A. No.").

<sup>238</sup> Helton Declaration at ¶3.

<sup>239</sup> Helton Declaration at ¶4.

<sup>240</sup> Helton Declaration at ¶6.

<sup>241</sup> Helton Declaration at ¶5. Dr. Helton notes that even ISI's initially promised training regime  
would be insufficient if, as in the program ISI actually put in place, (1) the "expert" evaluators  
had no medical training and no educational training, and (2) ISI gave inaccurate representations  
during training about the learning curve for robotic surgery.

<sup>242</sup> Helton Declaration at ¶5.

1 program from the originally proposed training paradigm that was submitted to  
2 the FDA and it was inexcusable to do so for the reasons they state. Further, to  
3 suggest that any surgeon could be adequately trained to perform any type of  
4 major surgery using the da Vinci surgical system after only the level of training  
5 proposed is unfounded and unsupported by any data, a leap of faith, potentially  
6 unsafe, and irresponsible.

8. ... It was *not* reasonable to reduce or scale back that training program as ISI  
9 did. Such a reduction in training could put patients at risk; the reasons stated by  
10 ISI for reducing that training do not justify that risk. The training program  
11 ultimately adopted by ISI and applied to Dr. Bildsten was inadequate and  
12 unreasonable to ensure patient safety.<sup>[243]</sup>

7 Moreover, Dr. Helton opines that, by the time of the Taylor surgery, ISI should have known  
8 (and warned) about the true nature of the learning curve for robotic surgery.<sup>244</sup> This  
9 knowledge was readily available from a host of published literature, much of which was  
10 authored by ISI's "own paid consultants[.]"<sup>245</sup> In fact, ISI's most prominent consultant, Dr.  
11 Vipul Patel, stated recently (after reviewing literature available in 2008) that the learning curve  
12 "to achieve *basic competency* for robotic radical prostatectomy" has been estimated to be  
13 between 20 and 25 cases.<sup>246</sup> In fact, when training its sales persons, ISI tells those sales  
14 persons that a surgeon's 11<sup>th</sup> through 20<sup>th</sup> procedures are the "Competence Development"  
15 stage.<sup>247</sup>

16 Dr. Helton, based on his review of the literature available to ISI in September 2008,  
17 concludes that ISI acted unethically in failing to fully disclose the nature of the learning curve:

18 ISI had an ethical responsibility to inform Dr. Bildsten that it would likely take  
19 him 20 to 40 procedures before he could safely perform unsupervised da Vinci

20 <sup>243</sup> Helton Declaration at ¶¶7-8.

21 <sup>244</sup> Helton Declaration at ¶¶9-13.

22 <sup>245</sup> Helton Declaration at ¶11.

23 <sup>246</sup> PT-232 (Patel et. al, *Difficult Conditions in Laparoscopic Urologic Surgery* (ISBN 978-1-84882-104-0), Chapter 16: "Difficulties in Robotic Radical Prostatectomy") at 209 (emphasis added).

<sup>247</sup> PT-73; Exhibit A to Mullenix Declaration (Daniels Deposition) at 194:8-196:3 (PT-73 accurately reflects the clinical sales process while Damon Daniels was at ISI.)

1 prostatectomy on the average patient, and 50 procedures before he could safely  
2 perform unsupervised da Vinci prostatectomy on a patient like Fred Taylor who  
3 was not an ideal robotic surgical candidate, especially for a novice surgeon on  
4 the robot.<sup>248</sup>

5 According to Helton, ISI “should also have given warnings of this nature to Harrison Medical  
6 Center.”<sup>249</sup> As Helton notes, ISI had “numerous”<sup>250</sup> opportunities to provide this information  
7 to Harrison and Dr. Bildsten, and its decision not to do so was “irresponsible and reckless.”<sup>251</sup>

#### 8 **H. ISI’s business model.**

9 When ISI formed, there was no market for robotic surgery devices. ISI recognized  
10 even in the late 1990s that one of its “big issues” was the surgeons’ perception of “how user  
11 friendly or patient specific” its robot was.<sup>252</sup> It also recognized that it would have to sell  
12 initially only to “large, high-volume tertiary care centers who can make the huge capital  
13 investment.”<sup>253</sup> It recognized that creating a demand for its “high cost”<sup>254</sup> product would  
14 depend using patients to create financial pressures on surgeons: “The last thing a surgeon  
15 wants is to have a patient walk in and talk about a friend who had a procedure done minimally  
16 invasively and have to say, ‘I can’t do that,’ because he knows the patient will look for another  
17 doctor.”<sup>255</sup> But even in the 1990s, ISI’s goal was to drive the demand for its robot to such an  
18 extent that even small hospitals would be forced to purchase the robot: “Ten years from now,  
19 will we find these systems in 50-bed hospitals? ... I think it’s a real possibility.”<sup>256</sup>

ISI’s method of achieving that reality is summed up in its sales motto: “Driving the

20 <sup>248</sup> Helton Declaration at ¶15.

21 <sup>249</sup> Helton Declaration at ¶15.

22 <sup>250</sup> Helton Declaration at ¶18.

23 <sup>251</sup> Helton Declaration at ¶19.

<sup>252</sup> PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2239.

<sup>253</sup> PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2243.

<sup>254</sup> PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2238.

<sup>255</sup> PT-240 (“Has the Real MIS Revolution Finally Arrived”).

<sup>256</sup> PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2243.

1 Curve.”<sup>257</sup> The “curve” in question is the “adoption curve” for robotic surgery,<sup>258</sup> i.e., the  
2 extent to which surgeons are performing given surgeries with the da Vinci robot as opposed to  
3 with open procedures or even non-robotic laparoscopy. ISI’s express goal was to make the use  
4 of its robot the “Standard of Care”<sup>259</sup> for surgeons. And its sales documents from 2007 show  
5 that ISI was, at that time, intensely focused on “da Vinci Prostatectomy” (“dVP”): “2007  
6 Marketing Strategy: dVP in every account! [<sup>260</sup>] ... Drive incremental dVP growth at all  
7 hospitals!”<sup>261</sup> Pushing “dVP” in 2007 was labeled, to ISI’s sales trainees, as ISI’s “**Highest**  
8 **Priority**”.<sup>262</sup>

9       ISI’s efforts were remarkably successful. By the end of 2007, according to ISI, more  
10 than 60 percent of all prostatectomies nationally were being performed with the da Vinci  
11 robot.<sup>263</sup> Locally, by 2008, ISI had already sold (multimillion dollar) robots to eight Seattle-  
12 and Tacoma-area hospitals.<sup>264</sup> Swedish Medical Center had already purchased a *second*  
13 robot.<sup>265</sup>

14       By July 2008, ISI’s procedure goals for dVP had grown even more ambitious. ISI’s  
15 July 2008 Sales and Marketing Plan demanded that that its sales force “[d]rive dVP to  
16 standard-of-care in every market by achieving a minimum of 20 dVPs in every [hospital], in  
17 every quarter.”<sup>266</sup> Higher level salespersons were responsible for a “minimum” of six  
18

19 <sup>257</sup> See, e.g., PT-29 at 414.

20 <sup>258</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 188:22-23.

21 <sup>259</sup> PT-29 at 409.

22 <sup>260</sup> By “account,” ISI was referring to hospitals that had purchased robots.

23 <sup>261</sup> PT-29 at 412.

<sup>262</sup> PT-29 at 404.

<sup>263</sup> PT-1 at 1016.

<sup>264</sup> PT-1 at 1019.

<sup>265</sup> PT-1 at 1019.

<sup>266</sup> PT-149 at 31894.

1 “greenfield” sales in 2008.<sup>267</sup> “Greenfields” were hospitals buying a robot for the first time,  
2 with no prior surgical robotics programs. Thus, those salespersons were each required to sell  
3 robots to six *new* hospitals in a single year. Because major hospitals had each already  
4 purchased systems by that time, ISI’s sales force understood that *smaller* hospitals must be  
5 their focus. In the words of one of ISI’s local salesmen: “Hospitals like Harrison are our  
6 future.”<sup>268</sup>

7 Other high level ISI sales persons were required to make at least three “second system”  
8 sales in 2008.<sup>269</sup> To do so, those sales persons were required to “Create demand for additional  
9 da Vinci System acquisitions” by driving “procedure growth”<sup>270</sup> at hospitals that had already  
10 bought robots. By driving procedure growth, i.e., increasing the number of procedures at a  
11 given hospital that were performed with the robot, ISI could create “capacity and scheduling  
12 constraints” that would lead to “additional system sales.”<sup>271</sup>

13 To drive procedure growth, ISI trained a large section of its sales force in “clinical”  
14 sales. These “Clinical Sales Representatives” (“CSRs”) were judged and paid not on selling  
15 robots, but rather on the extent to which they were able to convince surgeons to *use* robots: i.e.,  
16 to “maximize the utilization of installed da Vinci Surgical Systems.”<sup>272</sup> ISI provided “case  
17 volume goals” to these CSRs, and it considered those goals “the only measure of success.”<sup>273</sup>

18 For this reason, ISI actually paid its CSRs through a quota system based on *how many*  
19 *procedures were performed in the hospitals to which the CSR’s were assigned.* For instance, in

---

20 <sup>267</sup> PT-149 at 31894.

21 <sup>268</sup> PT-188.

22 <sup>269</sup> PT-227 (Drive the Curves 2008) at 31895.

23 <sup>270</sup> PT-227 (Drive the Curves 2008) at 31895.

<sup>271</sup> PT-227 (Drive the Curves 2008) at 31895.

<sup>272</sup> PT-80; Exhibit A to Mullenix Declaration (Daniels Deposition) at 189:19-90:10.

<sup>273</sup> PT-192.

1 2008, the CSR assigned to Harrison Medical Center (Damon Daniels) was promised a \$65,000  
2 base salary.<sup>274</sup> However, if the surgeons to whom Daniels was assigned performed the  
3 required number (“quota”) of surgeries, Daniels would receive \$120,000 *more* per year plus a  
4 likely \$15,420 in commissions for additional instrument sales.<sup>275</sup> If Daniels’s surgeons  
5 performed more than 10 percent above quota, he received an automatic *additional* 15 percent  
6 bonus, making his total bonus \$138,000. Consequences for failure were similarly stark: failing  
7 to hit at least 90 percent of the quota would mean a 75 percent reduction in procedure-based  
8 bonuses for Daniels in 2008.<sup>276</sup> As Daniels’s manager (Sean O’Connor) warned him one  
9 month before the Taylor surgery: “Missing quota by one case is a significant financial hit.”<sup>277</sup>

10 To enable its CSRs to convince surgeons to use its robot, ISI made a massive  
11 investment in *clinical* training of its sales staff. In contrast with its one-day surgeon training  
12 program, ISI’s sales training was *nine* weeks long.<sup>278</sup> It consisted of a three-week distance  
13 education course, four<sup>279</sup> to six<sup>280</sup> weeks of intensive residential “Clinical and Sales Training”  
14 (“CAST”) and then two more weeks of “field training” with an experienced CSR known as a  
15 “Field Trainer,”<sup>281</sup> followed by another week of “advanced CAST” in California.<sup>282</sup> One of the  
16 purposes of this training was to develop the CSRs’ “Equal Clinical Stature skillsets,”<sup>283</sup> *i.e.*, to  
17 develop the CSRs’ understanding of anatomy and medical terminology so that they have

---

18 <sup>274</sup> PT-172 at 34222.

19 <sup>275</sup> PT-172 at 34222.

20 <sup>276</sup> PT-172 at 34222.

21 <sup>277</sup> PT-197.

22 <sup>278</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 168:14-19; *see also* Exhibit B to  
23 Mullenix Declaration (Nagel Deposition) at 50:16-17.

<sup>279</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 168:14-16.

<sup>280</sup> Exhibit K to Mullenix Declaration (Carson Deposition) at 47:17-22.

<sup>281</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 168:14-19.

<sup>282</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 159:20-22.

<sup>283</sup> PT-70.

1 credibility when “talking about clinical benefits” with surgeons.<sup>284</sup> All CAST training was  
2 held at ISI headquarters in California.<sup>285</sup>

3 Once the CSRs emerged from CAST and field training, ISI provided each CSR with a  
4 “Clinical Sales Manager.” The job of the CSM was to constantly monitor the CSR’s progress.  
5 The CSM would hold weekly meetings with a small group of CSRs to motivate the CSRs and  
6 refine their sales techniques. These CSMs even required the CSRs to read new sales books  
7 each quarter.<sup>286</sup> The book for the fiscal quarter in which Fred Taylor’s surgery occurred was  
8 called “Hardball Selling.”<sup>287</sup>

9 In addition to this constant monitoring, all of ISI’s sales force would meet annually for  
10 a week at a time at ISI’s “World Wide Sales Meetings.” At these meetings, ISI would continue  
11 the training by, for instance, teaching the CSRs how to persuade urologists that da Vinci  
12 Prostatectomy was a better option than brachytherapy, or external beam radiation therapy.<sup>288</sup>  
13 They would also further develop the CSRs’ “equal clinical stature” skillsets by providing  
14 scripts to be memorized in how to “handle objections” from surgeons about the limitations or  
15 difficulty of using of ISI’s robot.<sup>289</sup>

16 As a result of these trainings, ISI held high expectations for its CSRs. ISI’s CSRs were  
17 expected to “[b]ecome a clinical expert across all primary OR procedures” in which the robot  
18 could be used.<sup>290</sup> One of a CSR’s “core activities” was to “Develop surgeon competence.”<sup>291</sup>

---

20 <sup>284</sup> Exhibit P to Mullenix Declaration (Thompson Deposition) at 24:22-25:8.

21 <sup>285</sup> Exhibit K to Mullenix Declaration (Carson Deposition) at 48:14-22; Exhibit B to Mullenix  
Declaration (Nagel Deposition) at 136:7-9.

22 <sup>286</sup> PT-199; Exhibit I to Mullenix Declaration (O'Connor Deposition) at 189:1-8.

23 <sup>287</sup> PT-199; Exhibit I to Mullenix Declaration (O'Connor Deposition) at 189:1-8.

<sup>288</sup> PT-31.

<sup>289</sup> PT-102.

<sup>290</sup> PT-80; Exhibit A to Mullenix Declaration (Daniels Deposition) at 189:19-190:10.



1 ISI expected CSRs to position themselves “as a partner in the development of surgical teams,”  
2 and even “[d]evelop a clinical plan for each surgical team to insure they are capable of using  
3 the system independently within reasonable time frame.”<sup>292</sup> And ISI expected CSRs to  
4 “[d]rive utilization of the da Vinci” by “partnering with surgical teams to *review and select*  
5 *appropriate cases* and insure consistent usage of the da Vinci.”<sup>293</sup>

6 Importantly, other than the training they received at ISI, these CSRs had no medical or  
7 educational training. Damon Daniels, the CSR who worked with Dr. Bildsten, for example,  
8 had a 1995 business degree.<sup>294</sup> Nor has any other member of ISI’s sales force yet deposed in  
9 this case had any prior medical or educational training.<sup>295</sup> Nonetheless, ISI expected these  
10 CSRs to be able to successfully challenge reluctant surgeons to convert previously scheduled  
11 open surgeries into robotic surgeries.<sup>296</sup> As one ISI Clinical Sales Director put it to a group of  
12 CSRs over whom he had direct authority:

13 We’ve all invested a lot of energy into developing our Equal Clinical Stature skill  
14 sets. It is now a matter of putting all of that practice to action. Be proactive in  
15 finding cases to convert. Be prepared to challenge each trained surgeon every  
16 time you see a lap or open case. Be unsatisfied with the thought of ending a day  
17 without a converted case.<sup>[297]</sup>

18 “Converting,” in this context, means finding a scheduled operation that a surgeon has decided  
19 to do without a robot, and convincing him against his initial judgment, to operate with the da  
20 Vinci.

---

21 <sup>291</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 193:21-194:4; PT-57.

22 <sup>292</sup> PT-80; Exhibit A to Mullenix Declaration (Daniels Deposition) at 189:19-190:10.

23 <sup>293</sup> PT-80 (emphasis added); Exhibit A to Mullenix Declaration (Daniels Deposition) at 189:19-  
190:10.

<sup>294</sup> PT-33.

<sup>295</sup> Paragraph 6 of Mullenix Declaration.

<sup>296</sup> See, e.g., PT-70.

<sup>297</sup> PT-70; *see also* Exhibit L to Mullenix Declaration (Ziegler Deposition) at 13:4-7 (ISI sales  
policies do not differ in significant ways between different geographical areas).

1           ISI knew that its sales force would not be effective at challenging the clinical  
2 judgments of trained surgeons unless the sales persons believed fully in the value of da Vinci  
3 surgery. Accordingly, ISI chose not to teach its sales persons that new robotic surgeons might  
4 be dangerous to their patients,<sup>298</sup> that new robotic surgeons would have higher complication  
5 rates,<sup>299</sup> or “anything” that would make a CSR “question the value of da Vinci® surgery.”<sup>300</sup>

6           Instead, ISI actually minimized the danger that new robotic surgeons posed to patients  
7 by teaching its CSRs to pressure hospitals to adopt only minimal credentialing and privileging  
8 requirements. The primary credentialing protections that hospitals would adopt for patients of  
9 new robotic surgeons were (1) completion of ISI’s training program and (2) “proctoring,” i.e.,  
10 the personal supervision of a new robotic surgeon’s procedures by an experienced robotic  
11 surgeon for some number of cases. Proctoring, stood in the way of ISI’s goal of “driving” the  
12 adoption curve, however, because the higher a hospital’s proctored procedure requirement, the  
13 less likely a surgeon would be to incorporate the robot into the practice, for two main reasons.  
14 First, the proctor surgeon would have to be paid \$2,000-\$3,000 per procedure by either the  
15 hospital or the surgeon, which made it more difficult for the CSR to convince new surgeons to  
16 perform procedures with the robot.<sup>301</sup> Second, the proctor surgeon’s availability would limit  
17 the trainee surgeon’s ability to book cases, meaning the surgeons would be unable to perform  
18 as many procedures as they could otherwise perform.<sup>302</sup>

19           ISI was able to combat this proctoring problem by having its sales persons closely

---

20 <sup>298</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 169:16-19.

21 <sup>299</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 169:20-24.

22 <sup>300</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 169:25-170:5.

23 <sup>301</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 245:4-246:2.

<sup>302</sup> See PT-215 (“I have challenged him to get at least one more case on by the end of the month so that he can have the freedom to book his cases at his convenience, without having to worry about the logistics of a proctor.”).

1 associate themselves with the robotics steering and credentialing committees at the  
2 “Greenfield” hospitals.<sup>303</sup> These Greenfield hospitals relied so heavily on ISI’s expertise that  
3 ISI would sometimes even set the agendas for the steering committee meetings.<sup>304</sup>  
4 Credentialing boards in such situations would look to ISI for guidance in adopting  
5 credentialing criteria.<sup>305</sup> ISI’s non-medically trained sales persons would then respond by  
6 either (1) providing credentialing examples from other hospitals that had adopted only minimal  
7 requirements (and not providing those examples of hospitals that had adopted difficult  
8 requirements), or (2) outright telling the hospitals that their proposed credentialing  
9 requirements were too high, even if that proposed requirement was as low as five proctored  
10 surgeries.<sup>306</sup>

11 ISI’s efforts to “drive the curve” have worked. According to its website, 2,462 da Vinci  
12 systems have been installed in over 1,936 hospitals worldwide.<sup>307</sup> As explained below, the CSR  
13 whose conduct is primarily at issue in this case (Damon Daniels), also achieved great success as a  
14 result of ISI’s training. In fact, he was the top CSR in the entire world for the year of the Taylor  
15 surgery.<sup>308</sup> For context, ISI had 700 sales employees at the end of 2010.<sup>309</sup> Daniels was even  
16 promoted by ISI in 2009.<sup>310</sup>

---

18 <sup>303</sup> “Greenfield” was the term ISI uses to describe hospitals without a da Vinci.

19 <sup>304</sup> PT-192.

20 <sup>305</sup> See Exhibit A to Mullenix Declaration (Daniels Deposition) at 202:15-23; 203:23-204:3;  
21 205:3-9; 225:3-7; 225:13-16; Exhibit I to Mullenix Declaration (O'Connor Deposition) at  
22 140:18-141:5; 141:13-23; Exhibit M to Mullenix Declaration (Gillam Deposition) at 14:1-19;  
23 PT-137; Exhibit N to Mullenix Declaration (Sanders Deposition) at 26:20-25.

24 <sup>306</sup> See PT-137

25 <sup>307</sup> [http://www.intuitivesurgical.com/products/products\\_faq.html#19](http://www.intuitivesurgical.com/products/products_faq.html#19) (available: online; accessed  
26 Jan. 17, 2013).

27 <sup>308</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 66:18-20; PT-33.

28 <sup>309</sup> PT-257 (2011 ISRG Annual Report) at 10.

29 <sup>310</sup> PT-33.

1           **I.       The ISI “Recommendations,” “Clinical Pathway,” and “Partnership.”**

2           Although ISI denies in this litigation that it is willing or able to teach surgeons how to  
3 perform robotic procedures,<sup>311</sup> it admits that it provides each urologist it trains,<sup>312</sup> before the  
4 Sunnyvale training, with a document entitled: “The Clinical Pathway and Training Protocol for  
5 da Vinci Prostatectomy.”<sup>313</sup> When training its salespeople, ISI defines this Clinical Pathway  
6 document as a “[p]rescribed, stepwise approach for surgeons and OR staff to develop  
7 knowledge and skills using the da Vinci Surgical System *in clinical applications*.”<sup>314</sup> In fact,  
8 the CSRs understood that an ISI certification meant the surgeons had successfully completed  
9 “the protocol for their specialty” and were able to apply surgical skills “to procedural  
10 applications.”<sup>315</sup> CSRs were explicitly told: “All necessary training for surgeons and nurses is  
11 built into the clinical plan.”<sup>316</sup>

12           These representations about the comprehensive nature of ISI’s training program were  
13 consistent with those ISI made to hospitals and the medical community at large. For instance,  
14 in 2007, ISI’s California-based<sup>317</sup> marketing department authored a chapter in a “Robotic  
15 Urology”<sup>318</sup> textbook. The chapter stated without qualification that: “Intuitive Surgical’s  
16 ***Comprehensive*** Clinical Training Continuum helps ***ensure*** optimal safety, efficacy, and  
17

18 <sup>311</sup> Exhibit G to Mullenix Declaration (Curet Deposition) at 76:14-15 (“We aren't in the position  
19 to teach somebody how to do a procedure.”)

20 <sup>312</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 231:23-25 (“Q. Were there ever  
21 times when you didn't go over the clinical pathway with a surgeon? A. No.”).

22 <sup>313</sup> PT-42, Ex. A.

23 <sup>314</sup> PT 212 (emphasis added); Exhibit A to Mullenix Declaration (Daniels Deposition) at  
24 258:10-22; 211:17-18 (“I told [surgeons] ... here's our clinical pathway document, you know,  
25 you should abide by this”).

26 <sup>315</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 266:1-8.

27 <sup>316</sup> PT-30 at 10878; Exhibit B to Mullenix Declaration (Nagel Deposition) at 59:10-11.

28 <sup>317</sup> PT-104 at XXII.

29 <sup>318</sup> PT-104.

1 utilization of each Da Vinci system.”<sup>319</sup> ISI also provided Greenfield hospitals (including  
2 Harrison)<sup>320</sup> with a document, on ISI letterhead, that is entitled: “Recommendations for  
3 Building a da Vinci Robotic Surgery Program.”<sup>321</sup> That document recommends as a  
4 “fundamental best practice”<sup>322</sup> that surgeons “Follow the Prescribed Clinical Pathway,”<sup>323</sup>  
5 which “Your Intuitive Surgical Clinical Sales Manager (CSM) will establish ... with you.”<sup>324</sup>  
6 When presenting that document to Harrison during early sales meetings, ISI likewise told  
7 Harrison it was a “Best Practice” for “surgeons and staff” to “Follow Intuitive’s prescribed  
8 training pathway.”<sup>325</sup> Similarly, ISI told Harrison that “[p]artnership with Intuitive Surgical”  
9 was a “Best Practice” because ISI had “experience from 600 other launches”.<sup>326</sup> As part of that  
10 process, ISI even promised the trainee surgeons and new hospitals: “Your Clinical Sales  
11 Representative will help measure your progress against state-of-the-art technique.”<sup>327</sup> (ISI  
12 makes this representation to hospitals like Harrison even though its Chief Medical Officer  
13 claims ISI “is not in a position to measure a surgeon's performance against state of the art  
14 technique.”)<sup>328</sup> This is all part of ISI’s overarching assurance that it will play an active role in  
15 ensuring the success of the program: “The success of your implementation is a direct reflection  
16 of our effectiveness and our support.”<sup>329</sup> These educational and marketing materials all

17  
18  
19 <sup>319</sup> PT-104 at 259 (emphasis added).

<sup>320</sup> Exhibit K to Mullenix Declaration (Carson Deposition) at 32:19-33:2.

<sup>321</sup> PT-72.

<sup>322</sup> PT-72 at 1.

<sup>323</sup> PT-72 at 1.

<sup>324</sup> PT-72 at 6.

<sup>325</sup> PT-1 at 1026.

<sup>326</sup> PT-1 at 1026.

<sup>327</sup> PT-72 at 6.

<sup>328</sup> Exhibit G to Mullenix Declaration (Curet Deposition) at 99:23-100:1.

<sup>329</sup> PT-72 at 8.

1 originate from California.<sup>330</sup>

2           ISI’s “Recommendations for Building a da Vinci Robotic Surgery Program” document is  
3 also important in that it runs wholly counter to ISI’s central theme in its summary judgment brief:  
4 that ISI training pertains to nothing but “the use of the da Vinci System” and specifically *does not*  
5 pertain to “a specific medical procedure.”<sup>331</sup> In fact, ISI has a da Vinci Prostatectomy Procedure  
6 Guide that takes a urologist through every step of a robotic prostatectomy.<sup>332</sup> In the  
7 “Recommendations for Building a da Vinci Robotic Surgery Program,” surgeons are instructed  
8 that as part of their training, they are to “[l]earn the procedure guide.”<sup>333</sup> This is recommended by  
9 ISI as a “fundamental best practice.”<sup>334</sup>

10           Likewise, the Clinical Pathway document also states that it is a “Training Protocol” for  
11 a specific kind of *procedure*: “da Vinci Prostatectomy.” The Clinical Pathway states that it has  
12 been put “in place” to “ensure success in becoming a proficient robotic surgeon.”<sup>335</sup> And the  
13 Clinical Pathway also states that it represents the “best practices around the country[.]”<sup>336</sup>

14           Among these purported “best practices” was a requirement that “2 cases must be  
15 booked” before offsite training would even be allowed by ISI.<sup>337</sup> In other words, ISI required  
16 the surgeons to book patients for robotic surgery *before those surgeons had received any*  
17 *robotic training*. ISI even threatened: “Training will be cancelled if cases are not booked.”<sup>338</sup>

18 With respect to proctoring, ISI recommended as a “best practice” that each trainee surgeon

19 \_\_\_\_\_  
20 <sup>330</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 24:18-24. PT-104 at XXII.

<sup>331</sup> See, e.g., ISI MSJ at 12.

<sup>332</sup> PT-13.

<sup>333</sup> PT-73 at 6.

<sup>334</sup> PT-73 at 1.

<sup>335</sup> PT-42, Ex. A.

<sup>336</sup> PT-42, Ex. A.

<sup>337</sup> PT-42, Ex. A at HEDGES 0041.

<sup>338</sup> PT-42, Ex. A at HEDGES 0041.

1 have only two proctored cases before beginning to work unsupervised.

2 Perhaps the most striking aspect of Pathway, however, is its intense focus on  
3 commitment to robotic surgery. The Pathway states in its first paragraph that becoming “a  
4 skilled robotic surgeon” takes “a high level of commitment early in the case series[.]”<sup>339</sup> ISI’s  
5 sales persons even treat these Clinical Pathway documents as “contracts.”<sup>340</sup> The CSRs ask the  
6 surgeons to *sign* the “contracts.”<sup>341</sup> They do so for the express purpose of “gain[ing]  
7 commitment” from the trainee surgeon.<sup>342</sup> The CSRs then keep and maintain copies of those  
8 signed contracts,<sup>343</sup> telling the doctors that the CSRs will “help them maintain their  
9 commitment to robotic surgery” and “hold them accountable.”<sup>344</sup>

10 In gaining this commitment, the CSRs would position themselves so that the surgeons  
11 viewed them “as a partner.”<sup>345</sup> ISI even taught CSRs to portray themselves as “a strong  
12 partner” with the hospital.<sup>346</sup> As ISI put it, in the Recommendations document given to  
13 Greenfields: “Behind every successful robotic surgery program is not only a great deal of  
14 effort, but also a strong partnership with Intuitive Surgical. . . . With this in mind, we would  
15 like to be closely involved in the development and execution of your program.”<sup>347</sup>

16 Despite their portrayal as “partners,” the CSRs were by no means fully forthcoming  
17

---

18 <sup>339</sup> PT-42, Ex. A.

19 <sup>340</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 230:1-6, 231:9-10.

20 <sup>341</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 259:13-16.

21 <sup>342</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 259:17-23.

22 <sup>343</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 231:9-11.

23 <sup>344</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 212:1-6.

<sup>345</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 212:14.

<sup>346</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 197:5-17.

<sup>347</sup> PT-72 at 1; see also PT-53 at 4143 (“Behind every successful da Vinci Surgery program is a strong partnership with Intuitive Surgical. Through the implementation of more than 930 da Vinci Surgery programs around the world, Intuitive Surgical has acquired the expertise and experience to facilitate development of a successful da Vinci program.”).

1 with the partner surgeons or hospitals. For instance, the CSRs would “never” tell the surgeons  
2 that the CSRs had a financial incentive to make sure that the surgeons actually performed  
3 procedures on humans with the robot.<sup>348</sup> Likewise, the CSRs would not tell the hospital  
4 steering committees that the CSRs “would be compensated based on the number of procedures  
5 done with the robot.”<sup>349</sup> Rather, ISI’s sales force learn to portray itself as entirely altruistic:  
6 “Everything we do is for the benefit of the patient.”<sup>350</sup>

7 **J. ISI approaches Harrison in April 2008.**

8 In April 2008,<sup>351</sup> Dave Carson, an ISI “Area Sales Manager,” began the process of  
9 convincing Harrison Medical Center to spend nearly \$1.8 million on a surgical robot that no  
10 Harrison surgeon knew how to use. Intuitive had trained Carson that, to make such a sale, it  
11 was important to “[f]oster a competitive landscape between hospitals and surgeons.”<sup>352</sup>

12 In doing so, Carson first recognized that, at that time, Harrison was “being challenged”  
13 by a new Gig Harbor hospital scheduled to open in 2009: Saint Anthony’s.<sup>353</sup> Carson knew  
14 that the urologists who were performing surgeries at Harrison were “in discussions with  
15 Franciscans to move their practice to Gig Harbor.”<sup>354</sup> Thus, to increase the pressure on Harrison  
16 to buy a robot, Carson began meeting with several Kitsap Peninsula surgeons, including the  
17 surgeons of Kitsap Colorectal, Kitsap Obstetrics and Gynecology, and Dr. Bildsten’s clinic:  
18 Kitsap Urology.<sup>355</sup> He convinced each of these groups to send letters to the executives at  
19

---

20 <sup>348</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 274:18-21.

21 <sup>349</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 275:10-13.

22 <sup>350</sup> Exhibit L to Mullenix Declaration (Ziegler Deposition) at 42:25-43:1.

23 <sup>351</sup> PT-105.

<sup>352</sup> PT-254 at 4100.

<sup>353</sup> PT-105.

<sup>354</sup> PT-105.

<sup>355</sup> See PT-251; Exhibit K to Mullenix Declaration (Carson Deposition) at 141:6-25.



1 Harrison, urging them to purchase a robot.<sup>356</sup>

2 At the same time, Carson began to exert pressure on Harrison by informing them that  
3 another of Harrison's "competitors," St. Joseph's Hospital in Tacoma (CHI), was in the  
4 process of buying its second robot.<sup>357</sup> Carson informed Harrison that "historically," CHI had  
5 requested "market protection" from ISI, i.e., that CHI would negotiate its purchase so that ISI  
6 would not sell robots to CHI's competitors in the same geographical area.<sup>358</sup> In other words, to  
7 create urgency for Harrison, ISI threatened to make an agreement with Harrison's competitor  
8 that would cause Harrison to lose patients. Internal ISI emails show that Carson and his  
9 Clinical Sales Manager worked together to convince Harrison that "market protection" was a  
10 real, potentially devastating, threat.<sup>359</sup>

11 While he applied all of this pressure, Carson also made numerous representations about  
12 the effectiveness of ISI's training program.<sup>360</sup>

13 Intuitive Surgical would like to be an integral part of your *da Vinci* Surgery  
14 program. We can:

- 15  Take the lead in coordinating *da Vinci* System installation, on-site training,  
staff in-servicing and surgeon training
- 16  Be part of the robotics steering committee if the hospital decides it is  
necessary

17 \* \* \*

- 18  Work with surgeons to develop and execute their clinical paths

19 \* \* \*

---

20 <sup>356</sup> See PT-251.

21 <sup>357</sup> Exhibit K to Mullenix Declaration (Carson Deposition) at 68:16-69:1.

22 <sup>358</sup> Exhibit K to Mullenix Declaration (Carson Deposition) at 73:1-7.

23 <sup>359</sup> Exhibit I to Mullenix Declaration (O'Connor Deposition) at 166:18-167:2; *see also* PT-258  
(June 6, 2008, email) at 32713 ("How did you want me to fwd this [market protection request]  
on to you?"); PT-259 to Mullenix Declaration (June 9, 2008, email) at 32287 ("Please do not  
commit to any market protection requests from St. Joe's until I get back to you on Wednesday.  
I will bring this up to them in person tomorrow night.").

<sup>360</sup> PT-108 at 30611.

- 1           □ Actively support cases in the OR; ...
- 2           □ Work with entire team to develop technical competency [<sup>361</sup>]

3 With respect to training, Carson told Harrison’s purchasing staff that ISI’s training programs  
4 were “designed to provide surgeons with the knowledge and skills necessary to utilize the da  
5 Vinci S Surgical System *for its intended use in a variety of endoscopic surgical procedures.*”<sup>362</sup>  
6 He told Harrison the training would be performed by “Experienced faculty.”<sup>363</sup> And he  
7 promised ISI would make “Surgeon led proctoring” available for \$3,000.<sup>364</sup> And to help the  
8 Harrison executives justify the expense of the purchase, Carson even provided them with a  
9 draft “Business Plan for the da Vinci Robotic Surgery System At Harrison Medical Center.”<sup>365</sup>

10           **K.     ISI illegally informs Harrison that its device has been “approved” by the FDA.**

11           ISI’s sales tactics included repeatedly suggesting to Harrison that the FDA had  
12 “approved” its device for certain surgical procedures. As even ISI’s retained FDA expert  
13 (Phillip Phillips) will explain at trial, FDA regulations bar device companies from doing  
14 anything to suggest that the FDA has given official approval of a device unless the  
15 manufacturer has successfully put the device through the rigorous Premarket Approval  
16 process.<sup>366</sup> Nevertheless, ISI directed communications squarely at Harrison that stated that its  
17 system had been “approved” by the FDA. For instance, the “Business Plan” that ISI provided  
18 to Harrison to support the purchase stated – misleadingly – that da Vinci gynecologic surgery

---

19 <sup>361</sup> PT-72 at 8.

20 <sup>362</sup> PT-108 at 30611 (emphasis added).

21 <sup>363</sup> PT-108 at 30611.

22 <sup>364</sup> PT-108 at 30611.

23 <sup>365</sup> PT-115.

<sup>366</sup> Exhibit O to Mullenix Declaration (Phillips Deposition) at 65:10-20 (“A. ... there is a regulation that prohibits suggesting that anything cleared through 510(k) is an approval by FDA. Q. And that regulation goes on to say that suggesting that is considered misleading and misbranding; correct? A. That's correct. Q. And in fact, when a device is cleared under 510(k), it does not indicate approval of the device by FDA? A. That's correct.”).

1 was “FDA-approved” in May 2005.<sup>367</sup> Likewise, another sales communication with Harrison  
2 states ISI’s robot “has been used in over 100 different types of surgical procedures.”<sup>368</sup> After  
3 listing a “sampling” of some 44 different procedures, ISI then states to Harrison: “*Certain*  
4 *clinical applications have not yet been approved in the US.*”<sup>369</sup> In reality, no procedure has ever  
5 been “approved” in the US.<sup>370</sup>

6 These communications to Harrison were not isolated incidents. In fact, one of ISI’s  
7 own paid consultants stated in a published article that the FDA had approved some forms of da  
8 Vinci surgery, and ISI would regularly provide that article to surgeons and hospitals.<sup>371</sup> ISI’s  
9 press release templates all stated, incorrectly, that the robot received “FDA approval ... in  
10 2001.”<sup>372</sup> Even ISI’s chapter in the textbook, *Robotic Urology* stated that ISI had received  
11 “U.S. Food and Drug Administration approval in 2005.”<sup>373</sup>

#### 12 **L. The Sale and Implementation at Harrison.**

13 Not surprisingly, Harrison ultimately agreed to buy a robot. The sale was finalized on  
14 June 20, 2008.<sup>374</sup> For the robot, and a five year service plan, Harrison paid \$1,754,500. With  
15 Harrison’s instrumentation order, the total purchase price was \$1,870,167.50.<sup>375</sup> Although  
16

---

17 <sup>367</sup> PT-115 at 30651.

18 <sup>368</sup> PT-108 at 30610.

19 <sup>369</sup> PT-108 at 30610 (emphasis added).

20 <sup>370</sup> See Parisian Report at 8 (citing 21 C.F.R. § 807.97 (1996)).

21 <sup>371</sup> See, e.g., PT-122 at 30 (“The da Vinci robot ... remains the only Food and Drug  
Administration (FDA)- approved master–slave surgical system still in existence able to provide  
the benefits necessary for the facile performance of robotic surgery.”); *id.* at 29 (stating Dr.  
Patel a “paid consultant” of ISI); Exhibit \_\_ to Mullenix Declaration (Thompson Deposition) at  
57:9-19 (stating that Thompson regularly provides PT-122 to customers).

22 <sup>372</sup> PT-229 (Press Release) at 31870; see also PT-260 (ISRG Q2 2012 Earnings Call Transcript)  
at 11 (“we are FDA approved in the US for chole”).

23 <sup>373</sup> PT-104.

<sup>374</sup> PT-110 at 30631.

<sup>375</sup> PT-120.

1 training of surgeons could be purchased separately from the robot, ISI included free training  
2 for six surgeons:

3 Intuitive shall provide training in the use of the System to Purchaser’s surgical  
4 personnel. As of the Effective Date of this Agreement the price for such  
5 Training shall be three thousand dollars (\$3000) per surgeon or physician’s  
6 assistant. Notwithstanding the above Intuitive agrees to provide training to six  
7 (6) surgeons as set forth above, at no charge, provided such training is completed  
8 within the first twelve (12) months of the Initial Term of this Agreement. [<sup>376</sup>]

9 Even before the sale was finalized, and as recommended by Carson, Harrison formed a  
10 “DaVinci Taskforce” (which was later renamed “Da Vinci Steering Committee”).<sup>377</sup> On the  
11 Committee were several of the surgeons who had written letters in support of the robot at  
12 Carson’s behest, including Dr. Bildsten.<sup>378</sup> These were also many of the surgeons who would  
13 receive Harrison’s free training slots (including Dr. Bildsten).

14 ISI’s Dave Carson, Sean O’Connor, and Damon Daniels attended the Task  
15 Force/Steering Committee.<sup>379</sup> All three salesmen were supervised by Glenn Vavoso, who  
16 worked out of ISI’s headquarters in California.<sup>380</sup> And the Commission Plans of all three  
17 salesmen were, at ISI’s demand, “governed by the laws of the State of California.”<sup>381</sup>

18 After the first meeting, O’Connor privately “expressed some doubt about the potential  
19 quality” of Harrison’s robotics program to Carson.<sup>382</sup> Carson reminded O’Connor “not to  
20 communicate any bias against Harrison” because “Hospitals like Harrison are our future.”<sup>383</sup>

---

21 <sup>376</sup> PT-110 at 30627.

22 <sup>377</sup> PT-82.

23 <sup>378</sup> PT-82.

<sup>379</sup> PT-82.

<sup>380</sup> Exhibit K to Mullenix Declaration (Carson Deposition) at 20:12-21:2; Exhibit B to Mullenix  
Declaration (Nagel Deposition) at 12:17-25.

<sup>381</sup> PT-221 at 34227; PT-210 at 34338; PT-261 at 34257.

<sup>382</sup> PT-188.

<sup>383</sup> PT-188.

1 He warned O'Connor that his concerns "shouldn't extend beyond you and me."<sup>384</sup>

2 In the meantime, the Committee had to decide credentialing criteria for robotic surgery  
3 at Harrison. No one on the Committee had any experience as a robotic surgeon. As one of the  
4 non-physician members of the Committee, Mickey Sanders, put it: "we had nothing to start  
5 with, and so ... we were looking to the reps ... to tell us what is the community standard in the  
6 other hospitals[.]"<sup>385</sup> Sanders said that ISI's representatives first provided the Committee with  
7 the Clinical Pathway Document—the document that sets a standard of "2 Cases or Hospital  
8 Protocol." According to Sanders: "That was kind of ... where we started[.]"<sup>386</sup> As Sanders  
9 continued to gather information on credentialing criteria, there continued to be "input from the  
10 da Vinci rep[.]"<sup>387</sup> According to the Steering Committee notes, this input included "samples of  
11 credentialing criteria" provided to Sanders by ISI's O'Connor or Carson.<sup>388</sup>

12 The following week, Sanders presented draft Credentialing Criteria to the Committee  
13 which, in every material respect, mirrored the ISI Clinical Pathway Document.<sup>389</sup> These  
14 criteria were later adopted.<sup>390</sup> Under the adopted criteria, Dr. Bildsten would not be allowed to  
15 perform robotic surgery until he had "documented successful completion of the hands-on  
16  
17

---

18 <sup>384</sup> PT-188.

19 <sup>385</sup> Exhibit N to Mullenix Declaration (Sanders Deposition) at 26:20-25.

20 <sup>386</sup> Exhibit N to Mullenix Declaration (Sanders Deposition) at 28:19-21; 27:17-21.

21 <sup>387</sup> Exhibit N to Mullenix Declaration (Sanders Deposition) at 33:13-17; 40:23-41:3 ("Q. And  
22 there was an earlier minute that we looked at from one of the earlier meetings where Mr. Carson  
23 or one of the Intuitive reps was going to get you material on credentialing. Did they ultimately  
do that? A. They did, but could I -- I couldn't sit here and tell you in what form it was, was it  
conversation, documents.").

<sup>388</sup> PT-82.

<sup>389</sup> PT-83; PT-229 (Bildsten Credentialing Application) at BATES 50158-50159; compare with  
PT-42 (Clinical Pathway).

<sup>390</sup> See PT- 262 (Bildsten Credentialing Application).

1 training ... required by the manufacturer.”<sup>391</sup> This was the training that ISI offered him in  
2 Sunnyvale, California.<sup>392</sup>

3 Another issue confronting the Committee was whether to get a new operating table for  
4 urology procedures. The Committee had money in its budget for a new table if necessary, and  
5 wanted to assure that any table it bought “can better accommodate obese patients.”<sup>393</sup> On June  
6 20, 2008, Dave Carson emailed Harrison’s Director of Surgical Services to confirm that “any  
7 table will work” with the robot.<sup>394</sup> Under this assurance, Harrison elected to not to buy a new  
8 table.

9 ISI also convinced Harrison through the Steering Committee process to make one of its  
10 staff members, Perla Lapidario, a dedicated da Vinci “robotics coordinator.” ISI even brought  
11 Ms. Lapidario to California for training as robotics coordinator.<sup>395</sup>

12 By the July 1 Steering Committee meeting, Carson was ready to hand the Harrison  
13 Steering Committee over to the “clinical team” of Damon Daniels (the CSR who would work  
14 directly with Harrison’s surgeons) and Sean O’Connor (Daniels’s supervisor).<sup>396</sup> At that  
15 meeting, according to Carson, Daniels and O’Connor “really established themselves as  
16 experts.”<sup>397</sup> They did so by again reinforcing the need for surgeons to “commit” to the Clinical  
17 Pathway.<sup>398</sup> They also did so by presenting ISI’s “marketing toolkit,” which ISI provided to  
18 hospitals as part of the sale. The toolkit included numerous marketing resources that would  
19

---

20 <sup>391</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 53:25-54:8.

21 <sup>392</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 54:6-8.

22 <sup>393</sup> PT-82 at 2.

23 <sup>394</sup> See PT-186, PT-187.

<sup>395</sup> Exhibit R to Mullenix Declaration (Lapidario Deposition) at 23:9-23.

<sup>396</sup> See PT-84; see also PT-191.

<sup>397</sup> PT-191.

<sup>398</sup> See PT-118 at 30808; PT-84.

1 allow ISI to help the hospital market da Vinci surgery to nearby patients.<sup>399</sup> Included in these  
2 resources were ISI brochures designed to tell potential patients: “Your doctor is one of the  
3 growing number of surgeons worldwide who’s been *successfully trained* in providing leading-  
4 edge treatments *such as da Vinci Prostatectomy*.”<sup>400</sup>

5 Finally, at the July 1 meeting, ISI presented a three-page implementation timeline for  
6 the da Vinci program at Harrison.<sup>401</sup> The plan ISI presented included detailed entries,  
7 complete with dates and persons responsible, for every step ISI suggested Harrison take,  
8 including the date credentials should be decided, install dates for the robot, the date the proctor  
9 would be scheduled for the first case, the date a “Core Four” staff team would be selected, the  
10 dates the surgeons would discuss the Clinical Pathway, and numerous other scheduled events.

11 According to the implementation timeline, the conversation with Dr. Bildsten and  
12 Damon Daniels regarding the Clinical Pathway should have taken place on July 2, 2008.<sup>402</sup> If  
13 the conversation did take place that day, then Daniels should have learned by that day that it  
14 would be impossible, given the patient volume of Dr. Bildsten’s urology practice, for Dr.  
15 Bildsten to meet the procedure volume requirements of the Clinical Pathway. For instance, Dr.  
16 Bildsten had completed only approximately 100 prostatectomy procedures in the 16 years since  
17 beginning his residency in 1992.<sup>403</sup> Thus, Dr. Bildsten could not be reasonably expected to be  
18 able to pick and choose “simple cases” with “Low BMI” if he was also to follow ISI’s  
19

---

20 <sup>399</sup> PT-118 at 30820 (“Integrated Marketing Implementation Plan, Print Ad Samples &  
21 Templates, Website Samples & Templates, Television Ad B-Roll, Patient Education Videos,  
22 Patient Hospital Posters, Patient Education Brochures & Seminars, and Referring Physician  
23 Seminar” materials).

<sup>400</sup> PT-152 at 2 (emphasis added).

<sup>401</sup> PT-121.

<sup>402</sup> PT-121 at 30838.

<sup>403</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 42:21-43:13.

1 instruction to perform “one case per week in order to get through the learning curve as quickly  
2 as possible.”<sup>404</sup> He simply did not have enough patients to be selective *and* follow the  
3 Pathway.

4 Even so, Dr. Bildsten committed to Daniels to follow the pathway.<sup>405</sup> Dr. Bildsten  
5 traveled to California for his one-day training at the porcine lab on July 17, 2008.<sup>406</sup> Damon  
6 Daniels traveled to California with Dr. Bildsten for training.<sup>407</sup> He did so to give Dr. Bildsten  
7 “a sense of comfort.”<sup>408</sup>

8 Because of the changes Mr. Nagel had made years prior, Dr. Bildsten received almost  
9 none of the training or assessment ISI had first promised to the FDA.

10 It is unclear what Dr. Bildsten did in the way of further training between his Sunnyvale  
11 training and his first procedures, which took place on July 28-29, 2008. Damon Daniels  
12 testified that surgeons will generally do some practice with him in the week leading up to their  
13 first procedures, though he had no specific recollection of Dr. Bildsten engaging in such  
14 practice.<sup>409</sup> Daniels explained that surgeons get value from this practice because, despite the  
15 fact that they have already been “certified” by ISI at the Sunnyvale training, they still have  
16 many questions about how to work the robot. Regardless, Daniels testified that Dr. Bildsten  
17 never refused any request Daniels ever made of him regarding training.<sup>410</sup>

18 Dr. Bildsten’s first two procedures were proctored by a doctor from Tennessee.<sup>411</sup> The  
19

---

20 <sup>404</sup> PT-42.

21 <sup>405</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 259:13-18; 231:23-25.

22 <sup>406</sup> PT-41 at 319.

23 <sup>407</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 39:15-40:2.

<sup>408</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 40:5-9.

<sup>409</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 180:20-181:7.

<sup>410</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 214:21-24.

<sup>411</sup> PT-96, PT-94.



1 proctor was arranged by Daniels through ISI's California-based Training Department,<sup>412</sup> and  
2 Dr. Bildsten had no choice in who would be his proctor.<sup>413</sup> (ISI required its proctors to agree  
3 that California law would govern any disputes between ISI and the proctors.<sup>414</sup>) Harrison paid  
4 a proctor fee to ISI, and the proctor was then paid by a check from ISI.<sup>415</sup> A traditional open  
5 prostatectomy in the hands of an experienced surgeon would take 2.5 hours.<sup>416</sup> ISI trained its  
6 sales persons to tell surgeons who were reluctant to adopt da Vinci that "most da Vinci  
7 surgeons today perform quality radical prostatectomy procedures in less than two hours." Dr.  
8 Bildsten's first two robotic procedures took 9.5 and 7.5 hours respectively,<sup>417</sup> despite the fact  
9 that both patients were relatively easy patients.<sup>418</sup>

10 ISI has produced no records to reflect any training or assessment of Dr. Bildsten's skills  
11 during or following those two proctored procedures. There is no evidence that Daniels  
12 suggested any "advanced" or additional training to Dr. Bildsten following these procedures.  
13 Dr. Bildsten did not have another opportunity to perform any prostatectomy, robotic or open,  
14 until Fred Taylor's surgery on September 9, 2008.<sup>419</sup>

---

17 <sup>412</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 49:7-50:2.

18 <sup>413</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 157:11-13.

19 <sup>414</sup> Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 63:22-64:15.

20 <sup>415</sup> Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 30:19-25. The hospital would  
have to pay ISI \$1,000 for the proctor's travel expenses, even if those travel expenses did not  
total \$1,000. The proctor received reimbursement from ISI only for his actual travel expenses.  
*Id.* at 59:2-60:4.

21 <sup>416</sup> PT-93 at 3263.

22 <sup>417</sup> PT-94.

23 <sup>418</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 139:25-140:15.

<sup>419</sup> PT-265 (Plaintiffs' Third Set of Interrogatories and Second Set of Requests for Production  
Propounded to Defendant Scott Bildsten, DO, with Responses) at RFP No. 39 (July 28, 2008-  
September 9, 2008).

1           **M.     The Taylor Surgery: Dr. Bildsten’s first non-proctored procedure.**

2           Fred Taylor had a biopsy sample diagnosed with prostate cancer on August 16, 2008.<sup>420</sup>  
3 He was 67 years old, had undergone coronary artery bypass graft surgery six years prior, and  
4 had undergone an umbilical hernia repair with mesh before that.<sup>421</sup> He was obese, with a BMI  
5 of 39. Even so, he was in good general health and would fish, swim, and golf.<sup>422</sup>

6           Open prostatectomy, the type of surgery that Dr. Bildsten had performed his entire  
7 career, is “routinely performed for localized prostate cancer, with excellent results and minimal  
8 morbidity.”<sup>423</sup> Dr. Bildsten had never had a complication during an open prostatectomy.<sup>424</sup> *da*  
9 *Vinci* Prostatectomy, on the other hand, is far more difficult for new robotic surgeons to safely  
10 perform. For instance, surgeons early in their *da Vinci* learning curve face the danger that the  
11 surgery will take a very long time.

12           ISI had trained Damon Daniels to believe that Bildsten had learned “all necessary  
13 skills” to perform *da Vinci* Prostatectomy. It had trained and authorized Daniels to “partner”  
14 with surgical teams “to review and select appropriate cases.” It had financially incentivized  
15 Daniels to try to convince surgeons to perform *every* prostatectomy with the robot. It had not  
16 trained him to seek a proctor for particularly challenging cases,<sup>425</sup> and Daniels recognized that  
17 the necessity of a proctor (at \$3,000 per surgery) can make it more difficult to convince  
18 surgeons to perform surgeries with the robot.<sup>426</sup> This problem is such an impediment to a  
19

20 <sup>420</sup> PT-263 at 100120 (9/5/2008 Surgical Note).

21 <sup>421</sup> PT-263 at 100120 (9/5/2008 Surgical Note).

22 <sup>422</sup> Exhibit S to Mullenix Declaration (Josette Taylor Deposition) at 55:10-56:7, 81:17-85:12,  
85:14-90:3.

23 <sup>423</sup> PT-93 at 3262.

<sup>424</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 134:20-22.

<sup>425</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 283:1-12.

<sup>426</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 245:17-246:4.

1 CSR's ability to meet his procedure quota that one ISI manager even explicitly ordered his  
2 CSRs: "Don't let proctoring or credentialing get in our way."<sup>427</sup> Thus, Daniels never made any  
3 attempt to even suggest that Bildsten have a proctor for the Taylor surgery.<sup>428</sup> Rather, with  
4 Daniels as his "partner," Dr. Bildsten decided to use the robot for the Taylor surgery.

5 The Taylor surgery took place on September 9, 2008. Though no surgeon proctor was  
6 present, Damon Daniels *was* present in the operating room for the surgery. Daniels believed it  
7 was his "responsibility" to "be there to help" the surgeons in the operating room, and he told  
8 the doctors as much.<sup>429</sup> According to Daniels, the device is so complex that questions remain  
9 even after (1) physicians have been trained and certified by ISI, (2) the staff has gone through  
10 an in-service with the CSR, (3) hospital credentialing requirements have been satisfied, (4) the  
11 surgeons have had additional practice with the robot, (5) the surgical team has had a dry run of  
12 the procedure, and (6) the surgeon has successfully completed two proctored surgeries:

13 It's a lot -- it's an intricate device. It is a lot of stuff. I mean, it's not just one  
14 instrument taken in and fire it, and then you're done. There's a lot of hand  
15 movements. There's a clutch. There's a camera. There's things to control that you  
16 need to be comfortable with, and it takes some time to do that. There's a lot of  
17 stuff to remember. And you know, after -- after those things you just mentioned,  
18 you know, it's not that easy to remember everything.<sup>[430]</sup>

19 One of ISI's proctors offered a similar assessment, testifying that the ISI representatives  
20 are present in the operating room "for the first couple hundred cases" because the robot is such  
21 a "complex machine."<sup>431</sup> In fact, when he was asked whether "it would be safe" for a surgeon  
22 to perform an unsupervised surgery without a proctor *or* a CSR there, the response by Daniels

23 <sup>427</sup> PT-99.

<sup>428</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 284:2-6.

<sup>429</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 206:5-24.

<sup>430</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 302:1-303:12.

<sup>431</sup> Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 78:20-21.

1 was: “I would prefer to be there.”<sup>432</sup>

2 With no proctor present, preventable errors were made from the start. First, Bildsten  
3 began the surgery by “insufflating” (inflating) Mr. Taylor’s abdomen at “20mmHg  
4 pressure.”<sup>433</sup> An unnecessarily high level of pressure exacerbates the harmful effects of a long  
5 surgery:

6 Insufflation pressures as high as 20 can cause renal failure. They can cause  
7 decreased cardiac output. They can cause ventilatory profusion and ventilation  
8 mismatches in the lung. The increased intra-abdominal pressure can push CO2  
9 into veins and cause an increase in end title CO2. They can cause acidosis.<sup>[434]</sup>

10 After Mr. Taylor was insufflated, it became clear that the operating table ISI had earlier  
11 recommended was actually unable to accommodate Fred Taylor, due to his size, in the proper  
12 “extreme Trendelenburg” position.<sup>435</sup> Daniels attempted to fix the problem by removing x-ray  
13 cassettes from the table to lower it, but even then the robot could not get over Mr. Taylor’s  
14 abdomen.<sup>436</sup> As a result, Mr. Taylor “had to be flattened out to just only slight Trendelenburg”  
15 in order for the robot to “dock.”<sup>437</sup>

16 “Ideal patient positioning” is necessary to prevent nerve damage during robotic  
17 prostatectomy due to “the potential for long operative times at the beginning of the learning  
18 curve[.]”<sup>438</sup> Use of the “slight Trendelenburg” position decreases visibility, further prolonging  
19 the surgery.<sup>439</sup> The longer the surgery, the greater the risk of rhabdomyolysis<sup>440</sup> and excessive

20 <sup>432</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 303:13-20.

21 <sup>433</sup> PT-252 (Operative Note).

22 <sup>434</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 108:15-20.

23 <sup>435</sup> PT-252 (Operative Note).

<sup>436</sup> *Id.*

<sup>437</sup> *Id.*

<sup>438</sup> Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 101:18-102:1.

<sup>439</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 122:4-8.

<sup>440</sup> Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 81:8-82:3; 85:22-25.

1 blood loss.<sup>441</sup> Because Bildsten had not been trained about the dangers of proceeding without  
2 placing Mr. Taylor in steep Trendelenburg, and because Daniels did not warn Bildsten about  
3 those dangers,<sup>442</sup> the surgery continued.

4 At this point, Dr. Bildsten had not even gotten “on console,” meaning he had not yet  
5 taken the controls of the robot, even though Mr. Taylor had already been in the operating room  
6 and under anesthesia for over two hours.<sup>443</sup> The trouble continued, however, as Dr. Bildsten  
7 quickly discovered “a moderate amount of intestines still covering the lower pelvis.”<sup>444</sup> Dr.  
8 Bildsten did his best to proceed with the surgery robotically, but “it was difficult to maintain  
9 good vision for the posterior bladder neck dissection due to the intestinal contents continually  
10 getting into the visual field.”<sup>445</sup> Dr. Bildsten continued for “several hours of trying to get better  
11 visualization,”<sup>446</sup> but eventually decided to abandon the use of the robot. After Mr. Taylor had  
12 been in the operating room for eight hours and fifty minutes, the robot was finally undocked.<sup>447</sup>

13 By the time Dr. Bildsten undocked the robot, Mr. Taylor had already lost almost 1800  
14 milliliters (7.6 cups) of his blood.<sup>448</sup> And because Dr. Bildsten had already performed several  
15 of the procedural steps in the prostatectomy at that time, simply closing Mr. Taylor up at that  
16 point was not a safe option. He had to finish the prostatectomy, despite the fact that Mr. Taylor  
17 had already been under anesthesia for nine hours. This required a new, six inch incision, in  
18  
19

---

20 <sup>441</sup> Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 106:7-18.

21 <sup>442</sup> PT-266 (ISI’s Answers to Plaintiff’s Second Requests for Production).

22 <sup>443</sup> PT-264 (Lapidario Timeline).

23 <sup>444</sup> PT-252 (Operative Note).

<sup>445</sup> PT-252 (Operative Note).

<sup>446</sup> PT-252 (Operative Note).

<sup>447</sup> PT-264 (Lapidario Timeline).

<sup>448</sup> PT-264 (Lapidario Timeline).

1 addition to the five existing “port” holes in Mr. Taylor’s abdomen.<sup>449</sup>

2 Unfortunately, another problem was soon discovered: a two centimeter “tear” in the  
3 lower rectum.<sup>450</sup> The tear was not discovered until Mr. Taylor had been in the operating room  
4 for ten hours and 36 minutes.<sup>451</sup> Dr. Bildsten, upon discovering the tear, obtained an  
5 “intraoperative consult” from general surgeon Greg Fleischhauer.<sup>452</sup> Dr. Fleischhauer worked  
6 to surgically repair the tear, further extending the length of the surgery.<sup>453</sup>

7 ISI takes the position in its summary judgment brief that this tear was actually caused  
8 by Dr. Bildsten’s finger, during the open part of the procedure.<sup>454</sup> That position is directly  
9 contradicted by robotic urology expert Adam Ramin, M.D.:

10 Q Is it your opinion that it occurred during the da Vinci portion of the  
11 procedure before opening?

12 A Yes.

13 Q How did that happen?

14 A This is a portion where they were trying to again develop the  
15 Denonvillier’s fascia. And based on his operative report he said after several  
16 hours of trying to develop this area, they decided to convert to open surgery.  
17 This is an area which has a high risk of cutting into the rectum and not  
18 recognizing it. The rectum is only a few millimeters away from the  
19 Denonvilliers' fascia in this particular area. And if you have more visualization,  
20 if there is blood coming into the field and bowel is coming into the field, add it to  
21 physician's fatigue, add it to a certain level of frustration, and add it to a patient  
22 not being in a correct position, it's very hard to tell whether you're properly --  
23 you are in the proper space or not. Very high chance that the rectum is injured at

---

18 <sup>449</sup> PT-252 (Operative Note).

19 <sup>450</sup> PT-252 (Operative Note).

20 <sup>451</sup> PT-264 (Lapidario Timeline).

21 <sup>452</sup> PT-252 (Operative Note).

22 <sup>453</sup> PT-252 (Operative Note).

23 <sup>454</sup> See ISI’s Motion for Summary Judgment on All Claims at 11 (relying on Dr. Bildsten’s  
deposition testimony to support its claim that “[t]he rectal injury occurred after the da Vinci  
system had already been turned off, disconnected from Mr. Taylor, removed from the surgical  
field, and was sitting unused in the operating room.”); see also Exhibit Q to Mullenix  
Declaration (Bildsten Deposition) at 275:18-20 (“And I believe my finger slipped into -- you  
know, went into his rectum and caused the tear that was there.”).

1 that point.<sup>[455]</sup>

2 The general surgeon that Dr. Bildsten asked to repair the tear also casts significant doubt on  
3 ISI's "finger tear" theory. Dr. Fleischhauer testified at his deposition that the tear "looked  
4 clean," not "ragged."<sup>456</sup> He further testified that the tear looked like "it was a surgical  
5 instrument ... that made the laceration."<sup>457</sup>

6 Regardless, after Dr. Fleischhauer repaired the tear, Dr. Bildsten still had to finish the  
7 procedure. Because it is necessary to slice through the urethra to remove the prostate (which  
8 surrounds the urethra like a donut), the final step of the surgery requires reconnecting the two  
9 sections. This process is called "anastomosis." "[W]atertight anastomosis is key to preventing  
10 urinary complications" in robotic surgery.<sup>458</sup> Watertight anastomosis is particularly important  
11 in robotic prostatectomy because, unlike in a traditional open procedure, robotic prostatectomy  
12 requires the arms of the robot to open the peritoneum.<sup>459</sup> Thus, in robotic prostatectomy: "The  
13 stakes are higher" with respect to achieving watertight anastomosis.<sup>460</sup> Dr. Bildsten,  
14 unfortunately, had not been trained by ISI to understand that opening of the peritoneum  
15 required watertight anastomosis, something not required in an open procedure, and he did not  
16 perform a watertight anastomosis on Mr. Taylor.<sup>461</sup> That failure directly contributed to several  
17 of Mr. Taylor's later complications.<sup>462</sup>

18 After 13 hours and 26 minutes, the surgery was finally considered "finished."<sup>463</sup> Even

---

19 <sup>455</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 79:10-80:3.

20 <sup>456</sup> Exhibit T to Mullenix Declaration (Fleischhauer Deposition) at 59:4-7.

21 <sup>457</sup> Exhibit T to Mullenix Declaration (Fleischhauer Deposition) at 59:8-19.

22 <sup>458</sup> Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 108:17-109:23.

23 <sup>459</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 104:10-105:3.

<sup>460</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 104:10-105:3.

<sup>461</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 257:12-258:14.

<sup>462</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 105:8-20.

<sup>463</sup> PT-264 (Lapidario Timeline).

1 so, Fred Taylor remained in the operating room as his surgeons waited for an ambulance to  
2 arrive so he could be transported from Harrison’s Silverdale facility to its Bremerton facility,  
3 which had an intensive care unit.<sup>464</sup> Nearly 15 hours after he first entered the operating room  
4 for his “minimally invasive surgery,” he was intubated in an ambulance.

5 The weeks and months to come showed that the results of the surgery were devastating.  
6 ISI does not even dispute that, because of the surgery, Mr. Taylor lost 3500 cubic centimeters  
7 (almost 15 cups) of blood,<sup>465</sup> had to have 7500 cubic centimeter “volume replacement,”<sup>466</sup> and  
8 underwent a consequent hypovolemic shock.<sup>467</sup> Nor does ISI dispute that the effects of the  
9 extraordinarily long surgery also caused Mr. Taylor to suffer from acute renal failure (kidney  
10 failure),<sup>468</sup> encephalopathy (impaired brain function),<sup>469</sup> acute rhabdomyolysis (break down in  
11 muscle tissue),<sup>470</sup> critical illness myopathy (muscle disease),<sup>471</sup> urethral anastomotic leak (non-  
12 watertight urethra),<sup>472</sup> femoral nerve injury,<sup>473</sup> stroke,<sup>474</sup> acute respiratory failure,<sup>475</sup> metabolic  
13 acidosis (abnormally acidic body fluids),<sup>476</sup> severe urethral contracture (shortened urethra),<sup>477</sup>  
14 pleural effusions (fluid on the lungs),<sup>478</sup> and permanent incontinence.<sup>479</sup> He also suffered a one-

---

16 <sup>464</sup> PT-264 (Lapidario Timeline).

17 <sup>465</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 9.

18 <sup>466</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 15.

19 <sup>467</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 19.

20 <sup>468</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 10.

21 <sup>469</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 11.

22 <sup>470</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 12.

23 <sup>471</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 21.

<sup>472</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 13.

<sup>473</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 16.

<sup>474</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 17.

<sup>475</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 18.

<sup>476</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 20.

<sup>477</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 24.

<sup>478</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 26.

<sup>479</sup> PT-248 (ISI’s Response to Plaintiffs’ First Requests for Admission) at RFA 25.



1 inch tear of his rectum during the surgery. ISI does not dispute that this tear caused him to further  
2 suffer a colourethral fistula (abnormal hole through his colon) and gram negative sepsis (bacterial  
3 infection).

4 Nine days after the robotic surgery, the repair of the rectal tear had broken down. The  
5 repair required another surgery and a diverting colostomy. He was not finally extubated until 17  
6 days after the robotic surgery. Five months after the robotic surgery, he had another procedure to  
7 begin repairing urinary problems. Ten months after the robotic surgery, he had a surgical  
8 implantation of an “artificial urinary sphincter” because he was still “totally incontinent of urine.”  
9 11 months after the robotic surgery, he had another surgery to reverse the earlier colostomy. A  
10 year after the robotic surgery, he had another surgery to repair the artificial urinary implant. The  
11 stresses from these numerous injuries and procedures left Mr. Taylor largely sedentary, which  
12 further increased the stresses on his heart. He succumbed to heart failure and died on August 25,  
13 2012. The pathologist who performed his autopsy concluded that “the enormous stress” placed on  
14 Mr. Taylor’s already diseased heart by the 2008 da Vinci Prostatectomy placed “additional severe  
15 demands” on Mr. Taylor’s heart.<sup>480</sup> For that reason, Mr. Taylor’s death was “a direct and  
16 proximate result of the complications of his robotic surgery on September 9, 2008.”<sup>481</sup>

17  
18 **N. Dr. Bildsten gives up on robotic surgery.**

19 Dr. Bildsten has stopped using robots to perform surgery. Though ISI tried to convince  
20 him to continue as a robotic surgeon, even sending him again to California for additional  
21  
22

23 <sup>480</sup> Declaration of William J. Brady at 4:16, 4:24.

<sup>481</sup> *Id.* at 5:8-10.

1 training,<sup>482</sup> he gave up robotics forever in early 2009.<sup>483</sup> Dr. Bildsten testified that robotic  
2 surgery was simply too difficult to learn to be worthwhile:

3 I was under the initial impression you would get a level of comfort within a  
4 certain number of cases. And as the -- as it went along, it seemed it was going to  
5 be much longer than that. . . . And after speaking with some other urologists in a  
6 similar situation who attempted to use the robotic -- the da Vinci robot for  
prostatectomy, a lot of others have decided not to proceed, as well. They found  
the learning curve so steep and lengthy that the level of comfort just took too  
long and decided to quit. And I was one of those.<sup>[484]</sup>

7 Dr. Bildsten has also since explained that, when he first agreed to train with ISI, he believed that  
8 “the ISI training program had been approved by the FDA.”<sup>485</sup> He also believed, based on his  
9 conversations with ISI representatives, “that ISI training and two proctored surgeries was  
10 sufficient to achieve basic competency and safely perform unsupervised robotic surgeries.”<sup>486</sup> He  
11 explained at his deposition that, looking back, more proctored surgeries were necessary: “With the  
12 advantage of looking back, I would prefer to have more proctored cases . . . . a minimum of five,  
13 but possibly ten[.]”<sup>487</sup> Bildsten explained that having a proctor present not only provides the  
14 advantage of that proctor’s experience and knowledge, it also reduces the pressure on the novice  
15 surgeon: “As you’re doing the procedure and you realize that you’re really the only one in the  
16 vicinity that’s qualified to use the robot, you’re sort of out there on an island a little bit.”<sup>488</sup>

17 Dr. Bildsten believes he “likely would not have agreed to begin training on the robot” if he  
18 had been accurately informed about the amount of time to reach basic competency.<sup>489</sup> He believes  
19 if he had simply performed an open procedure on Mr. Taylor, “there may have been no

20 <sup>482</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 153:7-11.

21 <sup>483</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 29:20-21.

22 <sup>484</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 29:22-30:14.

23 <sup>485</sup> Bildsten Declaration at ¶3.

<sup>486</sup> Bildsten Declaration at ¶4.

<sup>487</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 181:17-25.

<sup>488</sup> Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 182:17-21.

<sup>489</sup> Bildsten Declaration at ¶6.

1 complications” and Mr. Taylor’s injuries, “if any, would have been significantly less.”<sup>490</sup> Had he  
2 been informed about the dangers of insufflation “at levels over 15 millimeters of mercury,” or  
3 of “the need to ensure a watertight urethral anastomosis,” he would have “conducted the Taylor  
4 surgery differently, in a way that would have reduced the risk of harm to Mr. Taylor.”<sup>491</sup>

### 5 **III. STATEMENT OF ISSUES**

6 1. Does the Washington Product Liability Act preempt negligence claims unrelated  
7 to the design, manufacture or distribution of a product?

8 2. Is there a genuine factual dispute about whether ISI undertook or assumed a duty  
9 to train Dr. Bildsten to perform robotic prostatectomies?

10 3. Is there a genuine factual dispute about whether ISI breached its assumed duty to  
11 train Dr. Bildsten with reasonable care?

12 4. Is there a genuine factual dispute as to whether ISI provided negligent warnings  
13 under the WPLA?

14 5. Is there a genuine factual dispute as to whether ISI’s conduct was a substantial  
15 factor in causing Mr. Taylor’s injuries?

### 16 **IV. LEGAL AUTHORITY AND ARGUMENT IN OPPOSITION TO ISI’S MOTION** 17 **FOR SUMMARY JUDGMENT**

#### 18 **A. Summary Judgment Standard**

19 Summary judgment is not appropriate unless “the pleadings, depositions, answers to  
20 interrogatories, and admissions on file, together with the affidavits, if any, show that there is no  
21 genuine issue as to any material fact and that the moving party is entitled to a judgment as a  
22 matter of law.” CR 56(c). ISI, as the moving party, “bears the initial burden of showing the

23 <sup>490</sup> Bildsten Declaration at ¶7.

<sup>491</sup> Bildsten Declaration at ¶9.

1 absence of an issue of material fact.” *Young v. Key Pharmaceuticals, Inc.*, 112 Wn.2d 216, 225,  
2 770 P.2d 182, 187 (1989). If ISI carries this initial burden, Mrs. Taylor must make a sufficient  
3 showing to establish the existence of at least a factual issue regarding any challenged element of  
4 her claims. *Id.* In making her response, Mrs. Taylor “cannot rely on the allegations made in its  
5 pleadings” but must set forth by affidavits or otherwise, specific facts showing that there is a  
6 genuine issue for trial. *Id.*, at 225-26. “A material fact is one upon which the outcome of the  
7 litigation depends.” *Clements v. Travelers Indem. Co.*, 121 Wn.2d 243, 249, 850 P.2d 1298, 1301  
8 (1993). “All facts are considered in the light most favorable to the nonmoving party,” here, Mrs.  
9 Taylor, and “summary judgment is granted only if, from all of the evidence, reasonable persons  
10 could reach but one conclusion.” *Vallandigham v. Clover Park School Dist. No.400*, 154 Wn.2d  
11 16, 26 109 P.3d 805, 810 (2005).

12 **B. Mrs. Taylor Is No Longer Stating Claims for Design Defect, Manufacturing**  
13 **Defect, Breach of an Express or Implied Warranty, Breach of Contract, or**  
14 **Violation of Washington’s Consumer Protection Act.**

15 Mrs. Taylor clarifies that she is not claiming that the da Vinci surgical system was  
16 defectively designed or that some defect in the robot itself was introduced in the manufacturing  
17 process. She is also no longer pursuing a claim for breach of an express or implied warranty or  
18 for breach of contract. Mrs. Taylor is also no longer stating a claim under Washington’s  
19 Consumer Protection Act.

20 **C. WPLA Does Not Preempt Negligence Claims Unrelated to the Design,**  
21 **Manufacture, or Sale of the Product.**

22 ISI claims that all common law negligence claims against it are preempted because it is a  
23 product manufacturer and distributor. This is incorrect. The Washington Product Liability Act  
24 (“WPLA”) preempts common law *product liability claims*, whether based in strict liability or  
25 negligence. It does not preempt all common law claims against a defendant that happens to be a

1 product manufacturer for activity other than its manufacture and distribution of the product. It is  
2 the nature of the claim, not the nature of the defendant, that controls. As a result, Mrs. Taylor’s  
3 claims against ISI for negligently training Dr. Bildsten and representing its training as sufficient  
4 are not preempted.

5 The Washington Supreme Court held that the WPLA preempted common law *product*  
6 *liability claims* in *Washington Water Power Co. v. Graybar Elec. Co.*, 112 Wn.2d 847, 853, 774  
7 P.2d 1199, 1203 (1989). The Court’s discussion of preemption and its holding emphasize  
8 repeatedly that only common law product liability claims are preempted; nothing in the decision  
9 indicates that preemption might apply to all common law claims against a defendant that  
10 happened to produce a product:

- 11 • “Two aspects of the WPLA are at issue in this case. First is the extent to which the  
12 WPLA preempts traditional common law remedies for product-related harms.”  
13 112 Wn.2d at 851, 774 P.2d at 1202 (emphasis added).
- 14 • “[I]t is understandable why [the plaintiff] is anxious to preserve the option of  
15 bringing product liability claims for economic loss under common law tort  
16 theories.” 112 Wn.2d at 853, 774 P.2d at 1203 (emphasis added).
- 17 • “[T]he WPLA means nothing if it does not preempt common law product liability  
18 claims.” *Id.* (emphasis added).
- 19 • “To be sure, the Legislature might have stated its intent to preempt common law  
20 product liability claims more certainly than it has in the WPLA.” *Id.* (emphasis  
21 added).

- 1           •        “Our holding that the WPLA preempts the variety of common law causes of action  
2                    for harms caused by product defects applies also to equitable claims for such  
3                    harms.” 112 Wn.2d at 855 n.4, 774 P.2d at 1204 n.4 (emphasis added).

4           The *Graybar* Court based its decision largely on the definition of “product liability claim”  
5 in RCW 7.72.010(4). That definition further confirms that only common law product liability  
6 claims, not all common law claims, are preempted. A product liability claim is defined as

7           any claim or action brought for harm caused by the manufacture, production,  
8           making, construction, fabrication, design, formula, preparation, assembly,  
9           installation, testing, warnings, instructions, marketing, packaging, storage or  
10           labeling *of the relevant product*. It includes, but is not limited to, any claim or  
11           action previously based on: Strict liability in tort; negligence; breach of express or  
12           implied warranty; breach of, or failure to, discharge a duty to warn or instruct,  
13           whether negligent or innocent; misrepresentation, concealment, or nondisclosure,  
14           whether negligent or innocent; or other claim or action previously based on any  
15           other substantive legal theory except fraud, intentionally caused harm or a claim or  
16           action under the consumer protection act, chapter 19.86 RCW.

17           RCW 7.72.010(4) (emphasis added). Thus, a product liability claim is one arising from the  
18           defendants’ specific actions regarding the “relevant product”;<sup>492</sup> it does not include every claim  
19           against a defendant which happened to produce a product. The Supreme Court in *Graybar*  
20           described the definition of product liability claim as “the operative centerpiece of the statute,  
21           linking together the important concepts of ‘claimant’ and ‘harm’ to describe the liabilities of  
22           product manufacturers and sellers for product-related injuries.” 112 Wn.2d at 854, 774 P.2d at  
23           1204. As it is the textual basis for the Court’s preemption decision, preemption cannot be any  
24           broader than the statutory definition of “product liability claim.”

25           No court applying Washington law has held that every claim against a product  
26           manufacturer, regardless of the specific theory, must be brought under the WPLA, although a

---

27 <sup>492</sup> “The ‘relevant product’ under this chapter is that product or its component part or parts,  
28 which gave rise to the product liability claim.” RCW 7.72.010(3).

1 number of courts have determined that specific claims are product liability claims which must  
2 be brought under the act. *See Washington State Physicians Ins. Exch. & Ass'n v. Fisons Corp.*,  
3 122 Wn.2d 299, 323, 858 P.2d 1054, 1066 (1993) (stating that because claim was predicated  
4 on alleged failure to warn of dangerous propensities of prescription drug, common law theories  
5 were preempted); *Laisure-Radke v. Par Pharmaceutical, Inc.*, 426 F.Supp.2d 1163, 1168-69  
6 (W.D. Wash. 2006) (dismissing common law negligence claims relating to side effects of  
7 drug); *Macias v. Saberhagen Holdings, Inc.*, 175 Wn.2d 402, 409, 282 P.3d 1069, 1073-74  
8 (2012) (“The WPLA is the exclusive remedy for product liability claims. ... ***Insofar as a***  
9 ***negligence claim is product-based***, the negligence theory is subsumed under the WPLA  
10 product liability claim.”) (emphasis added).

11 The training ISI provided Bildsten is no more a “product,” than a driver’s education  
12 course is a “product.” The WPLA defines a “product” as “any object possessing intrinsic value,  
13 capable of delivery either as an assembled whole or as a component part or parts, and produced  
14 for introduction into trade or commerce. Human tissue and organs, including human blood and its  
15 components, are excluded from this term.” Training is not a product. Because WPLA  
16 preemption applies only to product-based claims, Mrs. Taylor’s claims against ISI for its negligent  
17 training of Dr. Bildsten are not preempted. These claims sound in negligence, not product  
18 liability.

19 If Boeing were to open a flight school at Boeing field to teach pilots how to fly 747s, the  
20 actions of its flight school would be subject to common law principles of negligence, not the  
21 WPLA. This is true even if it gave free 747 training to a certain number of its customers’  
22 employees. If General Motors had an auto manufacturing plant in Washington, and decided to  
23

1 also provide loans on its cars to customers, its loan activities would be subject to state lending  
2 statutes and common law principles, not the WPLA.

3         Simply stated, ISI could have decided to just sell its robots and leave it to medical schools  
4 and hospitals to develop programs for training doctors to operate the equipment and to develop  
5 additional procedures in which the equipment could be safely used. If it had done so, ISI would  
6 be responsible only for defects in its robotic system or associated warnings and instructions.

7         But ISI did not want to wait to see what training programs, if any, would develop, and  
8 what uses, if any, were found for its robotic system. It decided to implement its own training  
9 program to prepare as many doctors as possible to use its system. It represented that program as  
10 being a “pathway to ensure early success for Robotic Prostatectomy.”<sup>493</sup> Essentially, ISI opened  
11 up a second business in support of its manufacturing business. It recognized that to sell its robots  
12 and the associated service and parts, it needed to have more and more surgeons trained to use the  
13 system. Hospitals would not buy a da Vinci robot if very few surgeons could use it. And if few  
14 hospitals had the system, the number of additional surgeons mastering the system each year would  
15 be small. The demand for additional ISI robots, therefore, would also be small. ISI had to “drive  
16 the curve.”

17         ISI did so by starting its own training program, in order to prepare more doctors to use its  
18 system, and be able to assure hospitals purchasing the system that demand for the robot would  
19 increase quickly. While this training program certainly supports ISI’s overall business plan, it is  
20 fundamentally different than attaching a warning label or enclosing set of instructions. Therefore,  
21 the claim for negligence in completing this undertaking—for providing an inadequate pathway for  
22

---

23 <sup>493</sup> PT-42 at 42.



1 Dr. Bildsten to take before working on live human beings—is not a product claim, but a common  
2 law negligence claim.

3 **D. There Are Material Issues of Fact Regarding Whether ISI Undertook to**  
4 **Provide Additional Training to Doctors Interested in Using its Robotic**  
5 **System and Whether It Breached that Duty.**

6 By arguing that all claims against it must be product liability claims, ISI essentially argues  
7 that its training program is just an extension of its product warnings or instructions. This is the  
8 most fundamental fact question in this case. Mrs. Taylor is prepared to show at trial that ISI  
9 undertook to do more than just provide instructions on how to operate its machine; it purported to  
10 prepare physicians, including doctors like Dr. Bildsten with no prior laparoscopic experience, to  
11 perform specific procedures and become “a skilled robotic surgeon.”<sup>494</sup> Unfortunately, ISI did so  
12 negligently, telling doctors that they were ready to perform surgeries immediately upon their  
13 return from ISI’s training center, and to do so without supervision after only two proctored  
14 surgeries, when ISI knew that it has not provided all the training it had represented as appropriate  
15 to the FDA, and it knew that the true pathway to safe, effective robotic surgery was much longer.

16 **1. Washington Law Imposes Liability for Negligent Performance of a**  
17 **Voluntary Undertaking**

18 Initially, there can be no doubt that under Washington law, a defendant may be liable for  
19 negligently performing a task it voluntarily undertakes to perform. One example is the rescue  
20 doctrine:

21 One who undertakes, albeit gratuitously, to render aid to or warn a person in danger  
22 is required by our law to exercise reasonable care in his efforts, however  
23 commendable. If a rescuer fails to exercise such care and consequently increases  
the risk of harm to those he is trying to assist, he is liable for any physical damages  
he causes.

---

<sup>494</sup> See PT-42, Exhibit A, at 1.

1 *Brown v. MacPherson's, Inc.*, 86 Wn.2d 293, 299, 545 P.2d 13, 18 (1975). Although this is often  
2 referred to in Washington as “the voluntary rescue doctrine,” the principle is broader: “In certain  
3 circumstances, a person may be liable in negligence if he or she gratuitously assumes a duty to act  
4 on behalf of another and fails to act with due care in performing that duty.” *Meneely v. S.R.*  
5 *Smith, Inc.*, 101 Wn.App. 845, 856, 5 P.3d 49, 55 (2000).

6 In *Meneely*, the court determined that a trade association, which undertook to establish  
7 safety standards for swimming pools and diving boards, could be held liable for doing so  
8 negligently.<sup>495</sup>

9 By promulgating industry wide safety standards that pool and board manufacturers  
10 relied upon, NSPI voluntarily assumed the duty to warn Mr. Meneely and other  
11 divers of the risk posed by this type of board on a Type II pool. It failed to exercise  
12 reasonable care in performing that duty, when it did not change the standard after it  
13 knew that studies showed the pool and board combination was dangerous for  
14 certain divers.

15 101 Wn. App. at 859-60, 5 P.3d at 57.

16 Similarly, in *Sheridan v. Aetna Cas. & Sur. Co.*, 3 Wn.2d 423, 439, 100 P.2d 1024 (1940),  
17 the Washington Supreme Court held that an insurance company, which had agreed under the  
18 terms of its policy with a building owner to inspect the building’s elevator and file required  
19 reports, was liable to a third person injured when the elevator malfunctioned, for inspecting  
20 negligently.<sup>496</sup>

---

21 <sup>495</sup> Notably, the *Meneely* court did not feel it necessary to wrestle with any question about  
22 whether such a claim would be preempted by the WPLA.

23 <sup>496</sup> A similar rule is stated in Restatement (Second) of Torts, § 324A, which provides,

One who undertakes, gratuitously or for consideration, to render services to another  
which he should recognize as necessary for the protection of a third person or his  
things, is subject to liability to the third person for physical harm resulting from his  
failure to exercise reasonable care to protect his undertaking, if

(a) his failure to exercise reasonable care increases the risk of such harm, or

1 Thus, although a manufacturer would not have any duty to train buyers how to use its  
2 product (beyond providing adequate instructions and warnings) simply because it built the  
3 product, if it undertakes to provide such training, it is liable if it does so negligently. This is true  
4 in the same way that a non-manufacturer, who undertook to provide training in the use of  
5 someone else's product, would be liable for doing so negligently.

6 If a party raises a question of fact regarding whether a defendant has assumed and  
7 breached a duty of care, the issue must go to the jury. *See Alston v. Blythe*, 88 Wn.App. 26, 37,  
8 943 P.2d 692, 698 (1997) (holding that plaintiff had raised a fact question as to whether a truck  
9 driver had assumed a duty to help her safely cross the road by testifying that the driver, who was  
10 stopped in the line closest to her, had waved her to cross); *Panitz v. Orenge*, 10 Wn.App. 317,  
11 319-21, 518 P.2d 726, 728-29 (1973) (finding jury question under facts very similar to *Alston*).

12 **2. There is Substantial Evidence that ISI Undertook to Train Doctors,**  
13 **Including Dr. Bildsten, to Use its Robot in Surgeries.**

14 The evidence discussed above establishes that ISI undertook to train doctors not just in  
15 how its machine worked, but in how to use that machine to perform operations. ISI created  
16 "clinical pathways" for its trainees, dictating a path from no robotic experience to performing  
17 surgeries without supervision on patients in a few short steps. "The Clinical Pathway and  
18 Training Protocol" was a "Prostatectomy" pathway and training protocol.<sup>497</sup> It stated it had been  
19 "put in place to ensure success in becoming a proficient robotic surgeon." ISI represents that the

---

20 (b) he has undertaken to perform a duty owed by the other to the third person, or

21 (c) the harm is suffered because of reliance of the other or the third person upon the  
undertaking.

22 Washington has not yet adopted Section 324A. *See Meneely*, 101 Wn.App. at 862 n.4 (noting  
23 that because Washington law supported trial court's finding that a duty existed, it did not have  
to consider Section 324A.

<sup>497</sup> PT-42, Exhibit A, at 1.

1 pathway was developed from “the best practices around the country.”<sup>498</sup> ISI specifically promised  
2 Harrison Hospital:

3 Intuitive Surgical training programs are designed to provide surgeons with the  
4 knowledge and skills necessary to utilize the da Vinci® S™ Surgical System for its  
intended use in a variety of endoscopic surgical procedures.<sup>[499]</sup>

5 The Clinical Pathway itself focused on ISI’s scaled-back training phases, including the  
6 off-site training at ISI’s Porcine Lab. That training, however, had to be immediately followed by  
7 2 proctored surgeries:

8 6. Off Site Training – Porcine Lab, 1-2 days.

- 9 • Live Skills Lab at ISI training center – 2 Cases must be booked before departure  
10 for lab to ensure early success. Training will be cancelled if cases are not booked.  
Training fee \$3,000.<sup>[500]</sup>

11 Given that surgeries need to be scheduled even before the training was received, and needed to be  
12 performed soon after the doctor returned from the training, ISI must have realized that the training  
13 it provided would be viewed as fully preparing surgeons to perform those procedures. In fact, ISI  
14 told its CSRs: “*All necessary training for surgeons and nurses is built into the Clinical*  
15 *Plan.*”<sup>501</sup>

16 ISI further represented to Harrison that it had expertise in starting a robotic practice and  
17 that its clinical pathway was the key to success. In April 2008, ISI made a presentation to  
18 Harrison. On a page titled, “Highlights of Best Practices,” ISI stated,

19 Consultant analyzed 20 robust robotic surgery programs to determine “Best  
20 Practices”. Essential activities include:

21 \* \* \*

- Partnership with Intuitive Surgical – experience from 600 other launches

22 <sup>498</sup> PT-42, Exhibit A, at 1.

<sup>499</sup> PT-108, at ISI30611.

23 <sup>500</sup> PT-42, Exhibit A, at 1.

<sup>501</sup> PT-30, at ISI10878 (emphasis added).

- Follow Intuitive’s *prescribed training pathway* – surgeons and staff<sup>502]</sup>

In fact, ISI has openly marketed its central role in surgical training. In one of its brochures, ISI summarizes its role in a hospital’s *da Vinci* surgery program.

Intuitive Surgical would like to be an integral part of your *da Vinci* Surgery program. We can:

- **Take the lead in coordinating *da Vinci* System installation, on-site training, staff in-servicing and surgeon training**

\* \* \*

- **Work with surgeons to develop and execute their clinical paths**
- Coordinate site visits, case observations and proctors
- **Actively support cases in the OR**; support surgeon as well as staff; provide verbal technical assistance in the safe and effective use of the *da Vinci* Surgical System
- **Actively work with surgeons to help advance *da Vinci* surgical skills** – e.g. scheduling inanimate labs to develop technical skills<sup>503]</sup>

ISI must have also known that Harrison, like other hospitals, was following its lead with respect to the amount of training required before surgeons like Dr. Bildsten could perform robotic surgery without supervision. Harrison’s *da Vinci* Steering Committee relied on information from ISI’s representatives, including “samples of credentialing criteria.”<sup>504</sup> Shortly after receiving these samples and ISI’s Clinical Pathway, the Committee started considering and eventually adopted draft Credentialing Criteria which mirrored ISI’s Clinical Pathway. Under the adopted criteria, Dr. Bildsten could not perform robotic surgery at Harrison until he “documented successful completion of the hands-on training ... required by the manufacturer.”<sup>505</sup> Three ISI representatives – Dave Carson, Sean O’Connor, and Damon Daniels – attended the Committee

<sup>502</sup> PT-1, at IS1026 (emphasis added)

<sup>503</sup> PT-72, at 8.

<sup>504</sup> PT-82.

<sup>505</sup> Exhibit Q to Mullenix Declaration (Bildsten deposition) at 53:25-54:8.

1 meetings, so ISI must be charged with knowledge that Harrison was relying on the training it  
2 provided.

3 In this regard, ISI argues that it cannot be held liable for Harrison’s credentialing  
4 decisions, such as its decision to allow Dr. Bildsten (and other doctors) to perform unsupervised  
5 robotic surgeries after they had only received ISI’s limited training and had two proctored  
6 surgeries. But Mrs. Taylor does not seek to hold ISI responsible for Harrison’s actions, only its  
7 own. ISI’s discussion of this point somehow manages to overlook the fact that the Harrison  
8 committee that investigated possible credentialing standards received all of its information from  
9 ISI, which had promised to partner with Harrison in developing standards.<sup>506</sup> As they were taught  
10 to do in their ISI training, ISI’s salespeople sat with the committee and provided “expertise” on  
11 what other hospitals were doing, with an eye toward preventing hospitals from adopting  
12 “credentialing guidelines ... that might be challenging in starting their program” (that is, difficult  
13 for doctors to satisfy quickly).<sup>507</sup> Because ISI undertook to provide expertise to Harrison  
14 regarding credentialing, it can be liable if it did so unreasonably, regardless of whether Harrison  
15 can be blamed for following its advice.

16 Even more importantly, there is no dispute that ISI knew Harrison decided to adopt the  
17 standards ISI recommended, allowing a doctor to be credentialed after completing the  
18 manufacturer’s training and two proctored surgeries. As a result, ISI was aware that Harrison and  
19 Dr. Bildsten were relying upon ISI’s training – and nothing else – to equip Dr. Bildsten to safely  
20 perform operations without supervision after only two proctored surgeries. ISI also knew that it  
21

---

22 <sup>506</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 225:13-16 (“Q. ... [A]re you  
23 aware of anything that Harrison had as they're making their credentialing decision that wasn't  
provided by ISI? A. No. I'm not aware of it.”).

<sup>507</sup> PT-137.

1 would take at least 50 robotic procedures before a new robotic surgeon would be sufficiently  
2 competent to perform robotic surgery safely on a patient like Fred Taylor.<sup>508</sup> Yet ISI never told  
3 Dr. Bildsten or Harrison that the training it provided was not adequate. By withholding this  
4 information in this context, ISI further confirmed that it was undertaking to train Dr. Bildsten.

5 ISI also commissioned step-by-step procedure guides describing specific surgical  
6 procedures to be done with the da Vinci robot. It handed out those procedure guides to surgeons  
7 seeking training for those procedures. It told hospitals, including Harrison, that doctors needed to  
8 “learn” its guides as “part of training” for robotic surgery.<sup>509</sup>

9 ISI also provided its training separately from the sale of its machines, further  
10 demonstrating that the training was not just a part of the sale of the robot. As the sales contract  
11 between ISI and Harrison demonstrates, hospitals or doctors could pay for training separate from  
12 the purchase price.<sup>510</sup> At the time, the price was \$3,000 per doctor.<sup>511</sup> And although Dr. Bildsten  
13 received his training through one of the training slots provided for no additional cost with the  
14 purchase, his training was no different from the training provided others.

15 ISI may claim that it cannot be liable for negligent training because in addition to the  
16 statements and conduct set forth above, it also often made fine print disclaimers of its ability to  
17 train “on procedures.” For example, the same document that tells surgeons to “[l]earn the  
18 procedure guide”<sup>512</sup> as “part of training”<sup>513</sup> also states, in fine print, and on the last page:  
19 “Intuitive Surgical does not provide clinical training ... or train in surgical procedures or  
20

---

21 <sup>508</sup> Helton Declaration at ¶15.

22 <sup>509</sup> PT-73 at 6.

23 <sup>510</sup> PT-110 at 30627.

<sup>511</sup> *Id.*

<sup>512</sup> PT-73 at 6.

<sup>513</sup> PT-73 at 6.

1 techniques.”<sup>514</sup> Likewise, ISI’s website at the time of the sale to Harrison described “Procedure  
2 Training” as one of “three components” of ISI’s “comprehensive training pathway.”<sup>515</sup> On the  
3 same page, ISI contradicted itself, stating: “Intuitive Surgical is in no way responsible ... for  
4 training in surgical procedure or technique[.]”

5 Pasting disclaimers at the end of documents to negate responsibility for things you have  
6 done in those documents might provide some defense if the plaintiff in this case were Dr.  
7 Bildsten or Harrison. But ISI’s behavior also negligently endangered an entire class of foreseeable  
8 victims: the patients of surgeons who did not know they had received inadequate training.

9 Disclaimer or no, ISI convinced every relevant decision maker that its Clinical Pathway,  
10 including the training in Sunnyvale, was sufficient to get surgeons ready to perform unsupervised  
11 procedures on live humans. To CSRs, ISI made clear that its training was for use of the robot  
12 “in clinical applications,”<sup>516</sup> or “procedural applications,”<sup>517</sup> and was “[a]ll necessary  
13 training.”<sup>518</sup> ISI told hospitals that it had a “*Comprehensive* Clinical Training Continuum”<sup>519</sup>  
14 and that it would measure surgeons’ progress “against state-of-the-art technique.”<sup>520</sup> It  
15 specifically told Harrison that its programs were “designed to provide surgeons with the  
16 knowledge and skills necessary to utilize the da Vinci S Surgical System for *its intended use in*

17  
18  
19 <sup>514</sup> PT-72 at 8.

20 <sup>515</sup> May 13, 2008, version portion of ISI website devoted to explaining training program to  
hospitals; Mullenix Declaration at ¶ 6.

21 <sup>516</sup> PT 212 (emphasis added); Exhibit A to Mullenix Declaration (Daniels Deposition) at  
258:10-22; 211:17-18 (“I told [surgeons] ... here's our clinical pathway document, you know,  
you should abide by this”).

22 <sup>517</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 266:1-8.

23 <sup>518</sup> PT-30 at 10878; Exhibit B to Mullenix Declaration (Nagel Deposition) at 59:10-11.

<sup>519</sup> PT-104 at 259 (emphasis added).

<sup>520</sup> PT-72 at 6.



1 *a variety of endoscopic surgical procedures.*”<sup>521</sup> And as noted, ISI told doctors to “[l]earn the  
2 procedure guide”<sup>522</sup> as “part of training.”

3 ISI wants to be let off the hook for its inadequate training program because it, sometimes,  
4 spoke out of both sides of its mouth: stating that its training was in procedures and would ensure  
5 safety, followed by a disclaimer that it could not train in procedures nor ensure safety. A jury  
6 should decide whether those disclaimers allow ISI to avoid responsibility for its training program,  
7 *i.e.*, whether ISI *undertook* to train in procedures in spite of its disclaimers. It should be noted that  
8 many of ISI’s documents did *not* contain these disclaimers. Most importantly, the Clinical  
9 Pathway document was disclaimer free.<sup>523</sup> In fact, Damon Daniels admitted that he would tell the  
10 surgeons, and wanted those surgeons to believe, that the clinical pathway would ensure the  
11 surgeon’s success in becoming a proficient robotic surgeon.<sup>524</sup>

12 For all of these reasons, there is clearly a factual question regarding whether ISI undertook  
13 to provide training to Dr. Bildsten on how to use the robot in surgery. Therefore, the jury must  
14 answer this question. If the jury determines that ISI’s assumed duties beyond the mere instruction  
15 and labeling of a product, product liability law does not apply, and the jury will have to determine  
16 whether ISI breached the duty it undertook.

17 **3. There is Substantial Evidence that ISI Negligently Trained Dr.  
18 Bildsten**

19 Because ISI undertook to provide training to Dr. Bildsten, it had a duty to provide  
20 reasonable training. Mrs. Taylor is prepared to show that ISI’s training was not sufficient to make  
21

22 <sup>521</sup> PT-108 at 30611 (emphasis added).

23 <sup>522</sup> PT-73 at 6.

<sup>523</sup> PT-42.

<sup>524</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 268:22-269:5.

1 doctors competent to perform robotic surgery and that ISI withheld this information from doctors  
2 and hospitals while encouraging them to practice on patients.

3 As explained fully in Section II(G) above, the training actually provided to Dr. Bildsten  
4 was deficient in many ways. At the outset, ISI's trainers were not "expert" in any way: neither  
5 the Sunnyvale trainer nor Damon Daniels had any prior medical or educational expertise.<sup>525</sup>  
6 Moreover, as Dr. Helton has opined, the training program implemented as a whole "lacks depth  
7 and breadth, is incomplete, and is potentially unsafe."<sup>526</sup> Specifically, the program was not  
8 "comprehensive," was not marked by "consistent" assessments, was not conducted by  
9 "experts," and was not conducted using developed "metrics."<sup>527</sup> Rather, the assessments that  
10 were conducted were either not tests at all (such as the ten question online quiz for Phase One  
11 on which it was impossible to provide a wrong answer), or they were part of a protocol (Phase  
12 Two training in Sunnyvale) that, outside extraordinary exceptions, has never been failed. There  
13 was at no point the promised training on insufflator settings,<sup>528</sup> and surgeons were never  
14 required to perform the specific surgical skills for a given surgery.<sup>529</sup> Dr. Bildsten certainly  
15 never removed a prostate in Sunnyvale: pigs do not have prostates.<sup>530</sup> Surgeons did not even  
16 self-assess on specific skills, let alone their ability to perform specific procedures.<sup>531</sup> Phase  
17

---

18 <sup>525</sup> Helton Declaration at ¶5.

19 <sup>526</sup> Helton Declaration at ¶7.

20 <sup>527</sup> Exhibit H to Mullenix Declaration (Lederer Deposition) at 77:24-78:2.

21 <sup>528</sup> PT-10 at 27609; Exhibit B to Mullenix Declaration (Nagel Deposition) at 47:14-15.

22 <sup>529</sup> Exhibit H to Mullenix Declaration (Lederer Deposition) at 45:5-10 ("As it relates to urology  
is nonspecific."); Exhibit G to Mullenix Declaration (Curet Deposition) at 63:16-19 ("Q. As I  
am understanding what you're saying, you're saying ISI does not train on how to do procedures,  
including robotic prostatectomy. A. That's correct."); at 76:14-15 ("We aren't in the position to  
teach somebody how to do a procedure.").

23 <sup>530</sup> PT-243 (Lieberman Article Excerpt) at 18 ("pigs have no fat or prostate gland").

<sup>531</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 79:21-23, 81:8-18.

1 Three did not require practice of procedures on cadavers;<sup>532</sup> it consisted solely of a dry run  
2 without an anesthesiologist.<sup>533</sup> At most, the surgeon might come in on his or her off-time to  
3 practice, though Damon Daniels cannot remember if Dr. Bildsten was actually required to even  
4 do that.<sup>534</sup> Dr. Bildsten was offered nothing with respect to Phase Four before actually  
5 performing (proctored) procedures on live humans.<sup>535</sup> ISI did not train Dr. Bildsten in the  
6 dangers of excessive blood loss, the dangers of extremely long surgeries, proper insufflation  
7 techniques, or the need for a watertight anastomosis after violating the peritoneum with robotic  
8 arms.<sup>536</sup> Patient positioning was discussed only insofar as surgeons (many of whom, like  
9 Bildsten, had no laparoscopic experience) were told “that it should be similar to what they  
10 would be doing laparoscopically.”<sup>537</sup> ISI does not surgeons train on patient selection.<sup>538</sup> And  
11 perhaps most importantly, it does not provide them with realistic expectations about the truly  
12 steep learning curve for robotic surgery.<sup>539</sup> Rather, ISI discusses the learning curve as though  
13 the only issue were surgeon comfort, not patient safety and oncological outcome.<sup>540</sup> At trial, the  
14 testimony of Dr. Bildsten, Dr. Ramin, Dr. Lohrasbi, and Dr. Helton will show the danger that  
15  
16  
17

---

18 <sup>532</sup> See Exhibit I to Mullenix Declaration (O’Connor Deposition) at 53:23-54:9, 54:11-12.

19 <sup>533</sup> Exhibit I to Mullenix Declaration (O’Connor Deposition) at 54:11-12 (training between  
20 offsite training and first cases consists of 45 minute dry run the night before the first case);  
21 Exhibit B to Mullenix Declaration (Nagel Deposition) at 74:4-5.

22 <sup>534</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 180:20-181:7.

23 <sup>535</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 250:3-25.

<sup>536</sup> Exhibit H to Mullenix Declaration (Lederer Deposition) at 54:8-13 (blood loss); Exhibit B to  
Mullenix Declaration (Nagel Deposition) at 47:5-10 (long surgeries); Bildsten Declaration, at ¶  
9 (insufflation and anastomosis).

<sup>537</sup> Exhibit H to Mullenix Declaration (Lederer Deposition) at 103:21-23.

<sup>538</sup> Exhibit B to Mullenix Declaration (Nagel Deposition) at 42:14-25.

<sup>539</sup> Helton Declaration at ¶15.

<sup>540</sup> Helton Declaration at ¶¶16-17.

1 training of this nature can pose, particularly with a difficult surgical candidate like Fred Taylor.  
2 In Dr. Helton's words, ISI was "irresponsible and reckless."<sup>541</sup>

3 **4. Conclusion**

4 There are genuine factual disputes as to whether ISI undertook to provide training to  
5 doctor Bildsten on how to use the robot in surgery, and as to whether it did so negligently.  
6 Accordingly, ISI's motion for summary judgment on Mrs. Taylor's negligence claim should be  
7 denied.

8 **E. There is a Genuine Factual Dispute as to Whether, Under the WPLA, the**  
9 **Warnings Given by ISI Were Inadequate and Negligent.**

10 The WPLA provides that a manufacturer is liable for providing inadequate warnings or  
11 instructions:

12 (1) A product manufacturer is subject to liability to a claimant if the claimant's  
13 harm was proximately caused by the negligence of the manufacturer in that the  
14 product was not reasonably safe as designed or not reasonably safe because  
15 adequate warnings or instructions were not provided.

16 ...  
17 (b) A product is not reasonably safe because adequate warnings or instructions  
18 were not provided with the product, if, at the time of manufacture, the likelihood  
19 that the product would cause the claimant's harm or similar harms, and the  
20 seriousness of those harms, rendered the warnings or instructions of the  
21 manufacturer inadequate and the manufacturer could have provided the warnings or  
22 instructions which the claimant alleges would have been adequate.

23 (c) A product is not reasonably safe because adequate warnings or instructions  
were not provided after the product was manufactured where a manufacturer  
learned or where a reasonably prudent manufacturer should have learned about a  
danger connected with the product after it was manufactured. In such a case, the  
manufacturer is under a duty to act with regard to issuing warnings or instructions  
concerning the danger in the manner that a reasonably prudent manufacturer would  
act in the same or similar circumstances. This duty is satisfied if the manufacturer  
exercises reasonable care to inform product users.

---

<sup>541</sup> Helton Declaration at ¶¶20.  
PLAINTIFF'S OPPOSITION TO ISI MOTION FOR  
SUMMARY JUDGEMENT ON ALL CLAIMS

1 RCW 7.72.030(1). In this case, because ISI’s robotic surgical system is a medical device that can  
2 be legally used on patients only by licensed physicians, ISI’s duty is to provide adequate warnings  
3 and instructions to Dr. Bildsten. See *Terhune v. A.H. Robins Co.*, 90 Wn.2d 9, 13, 577 P.2d 975,  
4 977 (1978) (adopting the “learned intermediary” doctrine, under which “the duty of the  
5 manufacturer to warn of dangers involved in use of a product is satisfied if he gives adequate  
6 warning to the physician who prescribes it”).

7 ISI also claims that because this case involves a medical product, all product claims are  
8 also subject to Restatement (Second) of Torts § 402A, comment k.<sup>542</sup> This is incorrect. Comment  
9 k addresses the fact that certain products, such as prescription drugs and medical products, cannot  
10 be made entirely safe for their intended use. It addresses defective design, not failure to warn.  
11 Pursuant to comment k, “[s]uch a product, properly prepared, **and accompanied by proper**  
12 **directions and warnings**, is not defective, nor is it unreasonably dangerous.” *Id.* (emphasis  
13 added). “The seller of such products, **again with the qualification that** they are properly prepared  
14 and marketed, and **proper warning is given**, where the situation calls for it, is not to be held to  
15 strict liability for unfortunate consequences attending their use ....” *Id.* (emphasis added). As the  
16 Washington Supreme Court recognized in *Terhune*, “The comment does not purport to state what  
17 is ‘proper warning’ where such a product is involved.” 90 Wn.2d at 13, 577 P.2d at 977. As  
18 comment k does not address when a warning or instruction is adequate and Mrs. Taylor’s only  
19 remaining product claim is for improper warnings and instructions, comment k simply plays no  
20 role in resolving the issues in this case.<sup>543</sup>

21  
22 <sup>542</sup> The Washington Supreme Court adopted comment k in *Terhune*, 90 Wn.2d at 12-13, 577  
P.2d at 977.

23 <sup>543</sup> In *Young v. Key Pharmaceuticals, Inc.* (“*Young II*”), 130 Wn.2d 160, 922 P.2d 59 (1996),  
the Washington Supreme Court, in a case arising before the adoption of the WPLA, divided  
PLAINTIFF’S OPPOSITION TO ISI MOTION FOR  
SUMMARY JUDGEMENT ON ALL CLAIMS

1 Since the adoption of the WPLA in 1981, the standard for establishing a failure to warn  
2 claim is set forth in the Act, at RCW 7.72.030(1) (b & c). As quoted above, a manufacturer is  
3 liable if the product it supplies is “not reasonably safe because adequate warnings or instructions  
4 are not provided” or if the manufacturer should have learned of dangers of the product later, but  
5 fails to provide additional warnings reasonably necessary.

6 In order to determine if the warnings and instructions provided with the product are  
7 adequate, the jury must determine, “if, at the time of manufacture, the likelihood that the product  
8 would cause the claimant's harm or similar harms, and the seriousness of those harms, rendered  
9 the warnings or instructions of the manufacturer inadequate and the manufacturer could have  
10 provided the warnings or instructions which the claimant alleges would have been adequate.”  
11 RCW 7.72.030(1)(b); *see also* WPI 110.03 (failure to warn instruction containing similar  
12 language).

13 There is substantial evidence the risks associated with the use of ISI’s robotic system by  
14 those without sufficient experience or training were great, and rendered the instructions and  
15 warnings provided by ISI inadequate.

16 **1. There is a Question of Fact About Whether ISI’s Instructions or**  
17 **Warnings Were Inadequate**

18 Whether or not instructions and warnings are adequate is an inherently factual question.  
19 *See Estate of LaMontagne v. Bristol-Myers Squibb*, 127 Wn. App. 335, 343, 111 P.3d 857, 861  
20 (2005) (“Generally, the adequacy of a warning will be a question of fact.”), citing *Little v. PPG*

21 equally over the question of whether a common law failure to warn claim arising from a  
22 defective drug should be subject to a negligence standard or a failure to warn standard.  
23 *Compare* 130 Wn.2d at 168-69 (stating the negligence standard should apply) with 130 Wn.2d  
at 179-88 (stating that comment k does not apply to failure to warn claims, and strict liability  
should continue to apply). As discussed in the main body of this opposition, this decision is no  
longer relevant because RCW 7.72.030, not the common law, now governs failure to warn  
claims.

1 *Indus., Inc.*, 92 Wash.2d 118, 123, 594 P.2d 911 (1979), and *Haysom v. Coleman Lantern Co.*, 89  
2 Wn.2d 474, 573 P.2d 785 (1978). Such questions can be resolved on summary judgment only if  
3 “reasonable minds can reach only one conclusion from the admissible evidence.” *Estate of*  
4 *LaMontagne*, 127 Wn. App. at 343, 111 P.3d at 861, citing *Smith v. Safeco Ins. Co.*, 150 Wn.2d  
5 478, 485, 78 P.3d 1274 (2003). This is not such a case.

6 As Dr. Bildsten makes clear in his declaration, he was not warned that the training  
7 program was not FDA approved (and was given the contrary impression).<sup>544</sup> He was not warned  
8 the ISI training program *did not* prepare him to operate on live patients.<sup>545</sup> He was not warned  
9 that with no prior laproscopic experience, it was very unlikely he could achieve results  
10 comparable to his traditional approach for his patients until he had completed 100 or more robotic  
11 surgeries.<sup>546</sup> As Dr. Helton’s declaration makes clear, these deficiencies in the warning Dr.  
12 Bildsten received were “irresponsible and reckless.”<sup>547</sup>

13 Moreover, Dr. Bildsten was not warned of the need to ensure a watertight urethral  
14 anastomosis or of the dangers of insufflating patients during long surgeries at levels over 15  
15 millimeters of mercury.<sup>548</sup> He was not warned that da Vinci Prostatectomy should be performed  
16 only in steepest Trendelenburg.<sup>549</sup>

17 As Dr. Bildsten further explains in his declaration, contrary to ISI’s argument, Dr. Bildsten  
18 did not consider the information that was withheld from him obvious, and if he had been  
19 conveyed full information, it would altered his conduct, causing him to either not perform da

---

21 <sup>544</sup> Bildsten Declaration at ¶3.

22 <sup>545</sup> Bildsten Declaration at ¶4.

23 <sup>546</sup> Bildsten Declaration at ¶8.

<sup>547</sup> Helton Declaration at ¶20.

<sup>548</sup> Bildsten Declaration at ¶9.

<sup>549</sup> PT-266 (ISI’s Answers to Plaintiff’s Second Requests for Production) at RFP 51.

1 Vinci surgery on Mr. Taylor, or perform it in a different manner to reduce the risk of harm to Mr.  
2 Taylor.<sup>550</sup>

3 The jury may not agree with Drs. Bildsten and Helton, but there is no basis to find against  
4 their testimony as a matter of law.

5 **2. ISI Could Have Provided Adequate Instructions and Warnings**

6 The second requirement for establishing a failure to provide an adequate instruction or  
7 warning claim under RCW 7.72.030(1)(b) is showing “the manufacturer could have provided the  
8 warnings or instructions which the claimant alleges would have been adequate.” This is easily  
9 satisfied. ISI could very easily have provided proper warnings and instructions. For example,  
10 ISI’s early training program, at least as proposed to the FDA, would likely have provided  
11 adequate instructions.

12 Moreover, in light of ISI’s knowledge about the learning curve for da Vinci surgeries, ISI  
13 could easily have warned doctors, in these or similar words,

14 **It takes experience with 20 patients or more to achieve basic competency in the**  
15 **use of the da Vinci surgical system. Physicians should operate only under the**  
16 **supervision of a more experienced da Vinci surgeon until that point. It is**  
17 **strongly recommended that doctors not attempt to use the da Vinci system to**  
18 **operate on high risk patients, such as those who are obese, have major or**  
19 **multiple prior abdominal surgeries, or have diabetes or heart conditions, until**  
20 **more than 50 da Vinci surgeries have been performed.**

21 It made no such effort.

22 **F. ISI’s Negligent Training and Inadequate Instructions and Warnings are a**  
23 **Proximate Cause of Mr. Taylor’s Injuries and Her Damages**

24 In its motion, ISI argues in two different sections that Mrs. Taylor cannot establish that its  
25 conduct was a proximate cause of Mr. Taylor’s injuries. To make these arguments, ISI is forced  
26 to misrepresent Mr. Taylor’s injuries and the nature of her claims. Properly understood, there is

27 <sup>550</sup> Bildsten Declaration at ¶¶6-9.



1 ample evidence that ISI's breaches of its duty of care and its inadequate instructions and warnings  
2 caused Mr. Taylor's injuries and the resulting losses to his family.

3 "[I]ssues of negligence and proximate cause are generally not susceptible to summary  
4 judgment." *Owen v. Burlington Northern & Santa Fe R.R. Co.*, 153 Wn.2d 780, 788, 108 P.3d  
5 1220, 1223 (2005), quoting *Ruff v. King County*, 125 Wn.2d 697, 703, 887 P.2d 886 (1995)  
6 (additional citations omitted); *see also Hertog, ex. rel. S.A.H. v. City of Seattle*, 138 Wn.2d 265,  
7 275, 979 P.2d 400, 406 (1999) ("Breach and proximate cause are generally fact questions for the  
8 trier of fact.").

9 [I]n cases involving alleged medical negligence,<sup>551</sup> if a reasonable person could  
10 infer, from the facts, circumstances, and medical testimony, that a causal  
11 connection exists, the evidence is sufficient to survive summary judgment. The  
12 plaintiff need not establish causation by direct and positive evidence, but only by a  
13 chain of circumstances from which the ultimate fact required is reasonably and  
14 naturally inferable.

15 *Attwood v. Albertson's Food Centers, Inc.*, 92 Wn. App. 326, 330-31, 966 P.2d 351, 353 (1998),  
16 citing *Douglas v. Freeman*, 117 Wn.2d 242, 252, 814 P.2d 1160 (1991); *McLaughlin v. Cooke*,  
17 112 Wash.2d 829, 837, 774 P.2d 1171 (1989); and *Teig v. St. John's Hosp.*, 63 Wn.2d 369, 381,  
18 387 P.2d 527 (1963).

19 ISI argues that any failure to warn cannot have caused any harm because Dr. Bildsten  
20 admitted being told that he should choose patients with a relatively low BMI and relatively simple  
21 cases. But Dr. Bildsten had never had a complication in over 100 prostatectomies.<sup>552</sup> From this  
22 the jury can infer he was a competent, careful, conscientious surgeon. ISI undertook to train him  
23 in a new technique. After doing all the training they asked him to do, Dr. Bildsten then made a  
series of mistakes. Some of the mistakes had nothing to do with Mr. Taylor's weight—like failure

<sup>551</sup> The cause of action against ISI is not for medical negligence, but obviously, this case does  
involve injuries suffered in a medical procedure.

<sup>552</sup> Bildsten Declaration at ¶7.

1 to attempt a water-tight anastomosis and creating too great insufflation pressure. Admittedly, ISI  
2 never trained or warned on these issues and, as outlined above, there is evidence from which a  
3 jury could conclude these mistakes caused injury to Mr. Taylor.

4 ISI gave Dr. Bildsten a Clinical Pathway he could not possibly follow. He was set up to  
5 either fail in his “commitment” to do “one case per week” or in his commitment to only do simple  
6 patients for his early cases.<sup>553</sup> A jury could find that the Clinical Pathway document itself was  
7 negligently constructed and invited failure.

8 Additionally, the jury could agree with Drs. Bildsten and Helton that simply telling Dr.  
9 Bildsten to refrain from operating on patients with high BMI was not an adequate warning. In  
10 fact, Damon Daniels would tell surgeons that the longer they waited between procedures, the  
11 more their skills would degrade.<sup>554</sup> They could agree with Dr. Bildsten that if he had been given  
12 adequate warnings, things would have been very different: “there may have been no  
13 complications, and injury to Fred E. Taylor, if any, *would have been significantly less.*”<sup>555</sup> There  
14 is no basis to say otherwise as a matter of law.

15 ISI also states, “Dr. Bildsten testified at the time of the September 9, 2008 prostatectomy  
16 he felt well trained to use the da Vinci system.” This does not, as ISI implies, establish that he  
17 *was* well trained, just that he thought so at the time. As shown above, Dr. Bildsten now believes  
18 that he was not adequately prepared and that if told additional information by ISI, he would have  
19 acted differently. Mr. Taylor was injured in this case *because* ISI convinced Dr. Bildsten that he  
20 would be ready to perform robotic surgeries after a brief training and two proctored surgeries and  
21 Dr. Bildsten proceeded with understandable, but misguided confidence.

22 <sup>553</sup> PT-42 at 42.

23 <sup>554</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 292:7-10.

<sup>555</sup> Bildsten Declaration, at ¶ 7 (emphasis added)

1 In Section V.H. of its motion, ISI argues that Mrs. Taylor cannot establish any causal  
2 connection between its acts and the injuries involved in this case. This entire argument is based  
3 on two false premises: 1) that the only injury Mr. Taylor suffered was a rectal tear; and 2) that it  
4 is undisputed that the rectal tear occurred after Dr. Bildsten converted the Taylor surgery from  
5 robotic to open surgery.

6 As discussed above, Mr. Taylor suffered a number of harms in this surgery, including  
7 extreme loss of blood, hypovolemic shock, an extended period of time under anesthesia, acute  
8 renal failure (kidney failure), encephalopathy (impaired brain function), acute rhabdomyolysis  
9 (break down in muscle tissue), critical illness myopathy (muscle disease), urethral anastomotic  
10 leak (non-watertight urethra), femoral nerve injury, stroke, acute respiratory failure, metabolic  
11 acidosis (abnormally acidic body fluids), severe urethral contracture (shortened urethra), pleural  
12 effusions (fluid on the lungs), and permanent incontinence, all in addition to the rectal tear.<sup>556</sup>  
13 None of these injuries were solely caused by the rectal tear,<sup>557</sup> and many were directly related to  
14 the length of the surgery and Dr. Bildsten's difficulty in visualization within Mr. Taylor.<sup>558</sup>

15 Even if the rectal tear were the only injury, it is a disputed question of fact as to when it  
16 occurred. While Dr. Bildsten did assert in his deposition that he believed the tear did not occur  
17 until after he converted to an open procedure, and was caused by his finger, this is contradicted by  
18 the testimony of the surgeon who repaired the tear, Dr. Fleischhauer, and robotic urology expert  
19 Dr. Adam Ramin. Dr. Fleischhauer testified that the tear "looked clean," not "ragged" and that it  
20

21 \_\_\_\_\_  
22 <sup>556</sup> PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 9-13, 16-18, 20-  
21, 24-26.

23 <sup>557</sup> PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 9-13, 16-18, 20-  
21, 24-26.

<sup>558</sup> Swerdlow Declaration at ¶¶

1 looked like “it was a surgical instrument ... that made the laceration.”<sup>559</sup> Dr. Ramin testified at  
2 his deposition that, in his opinion, the tear occurred during the da Vinci procedure, as Dr.  
3 Bildsten’s reported difficulty visualizing in an area extremely close to the rectum, where there  
4 is “a high risk of cutting into the rectum and not realizing it.”<sup>560</sup>

5 Proximate cause is an issue for the jury here, just as it is in most cases.

6 **G. It Is Irrelevant that ISI and Its Clinical Sales Representatives Are Not Health**  
7 **Care Providers**

8 ISI argues extensively that neither it nor its clinical sales representatives are medical  
9 providers within the meaning of RCW 7.70.020. Mrs. Taylor never claimed otherwise. The  
10 services ISI performed or purported to perform were not health care. Chapter 7.70, Actions for  
11 Injuries Resulting From Health Care, is not at issue in this dispute between Mrs. Taylor and ISI.  
12 It does not follow, however, that ISI gets a free pass for its negligence and the negligence of its  
13 employees.

14 Nor is ISI’s negligence analogous to that of the pharmacist in *McKee v. American Home*  
15 *Products*, 113 Wn.2d 701, 782 P.2d 1045 (1989), on which ISI relies. ISI is not being sued for  
16 not second-guessing Dr. Bildsten; it is being sued for not training him properly and not providing  
17 him with information he needed to know to exercise his proper medical judgment. Mrs. Taylor  
18 does assert that, because ISI assumed the duty to train Dr. Bildsten and undertook to “partner”  
19 with him in the implementation of a robotic surgery practice, its responsibility to properly inform  
20 Dr. Bildsten continued into the operating room. But this is neither the heart of the cause of the  
21 action nor an intrusion into the doctor patient relationship. If ISI had trained Dr. Bildsten  
22 properly, he would have known everything he needed to know to treat Mr. Taylor safely before

23 <sup>559</sup> Exhibit T to Mullenix Declaration (Fleischhauer Deposition) at 59:4-19.

<sup>560</sup> Exhibit D to Mullenix Declaration (Ramin Deposition) at 79:10-80:3.

1 the operation started. ISI's presence in the operating room, in the person of Damon Daniels,  
2 simply gave ISI one last chance to correct its prior errors. If ISI had done so, it would not have  
3 intruded on Dr. Bildsten's decision-making, it would simply have made his training more  
4 complete.<sup>561</sup>

5 ISI's discussion of decisions from other jurisdictions holding that medical product  
6 representatives are not liable for medical malpractice is similarly beside the point. ISI is not being  
7 sued for not exercising proper medical judgment in the operating room. It is being sued because it  
8 undertook to train Dr. Bildsten (or warn and instruct him) and it did so negligently.

9 **H. Mrs. Taylor Is Not Making A Separate Claim Against ISI Regarding the**  
10 **Operating Table, Although its Advice Regarding the Table Is Evidence of the**  
11 **Extent of its Partnership with Harrison**

12 ISI argues that it has no liability for any claims relating to the operating room table used  
13 during Mr. Taylor's operation. Mrs. Taylor is not bringing a separate claim regarding the  
14 operating table. But ISI's assertion that it does not make recommendations to hospitals regarding  
15 tables is incorrect. In fact, after ISI represented that it would "partner" with Harrison in its  
16 development of a robotic surgery practice, Harrison's da Vinci Task Force wanted to "assure table  
17 selected can better accommodate obese patients."<sup>562</sup> Harrison followed up by asking ISI's Dave  
18 Carson regarding table choice,<sup>563</sup> and he responded that "any table will work."<sup>564</sup> Damon Daniels,

---

19 <sup>561</sup> There are also important differences between a pharmacist and ISI. As ISI points out in its  
20 brief, part of the Supreme Court's concern in *Mckee* was that imposing a duty on pharmacists  
21 would cause them to second guess numerous prescriptions to avoid liability, placing an undue  
22 burden on pharmacists and creating an antagonistic relationship between pharmacists and  
23 physicians. 113 Wn.2d at 716, 782 P.2d at 1053. Here, however, ISI's representative Daniels  
and Dr. Bildsten were in the same room for many hours, and Daniels was there precisely to  
assist and advise the doctor. As he was there to communicate with the doctor, there is no reason  
to believe that such communications would be burdensome, disruptive, or antagonistic.

<sup>562</sup> PT-82, at 2.

<sup>563</sup> PT-186.

<sup>564</sup> PT-187.

1 a recipient of the email, conceded at his deposition that he interpreted this as “a recommendation  
2 that any table will work with the da Vinci.”<sup>565</sup> While this does not constitute a separate claim, it is  
3 evidence of Harrison’s reliance on ISI, ISI’s knowledge of that reliance, and ISI’s partnership with  
4 Harrison. As ISI told Harrison: “The success of your implementation is a direct reflection of  
5 our effectiveness and our support.”<sup>566</sup> The inability of the ISI-trained operating staff to place  
6 Mr. Taylor in the proper surgical position, even with the help of Daniels, is evidence of the  
7 poor training and inadequate warnings that caused Mr. Taylor’s disastrous outcome.

8  
9 V. CONCLUSION

10 To be sure, there are many arguments ISI can make in an attempt to avoid liability in this  
11 case. Just as surely, all of those arguments require resolution of factual disputes in its  
12 favor. Ultimately, that may be the ultimate result in this case. But at this stage the Court must  
13 view all the facts and inferences in the light most favorable to plaintiffs. Such an analysis requires  
14 that ISI’s motions for summary judgment be denied.

15 DATED this \_\_\_\_\_ day of \_\_\_\_\_, 2013.

16  
17 \_\_\_\_\_  
18 Richard H. Friedman, WSBA # 30626

19 FRIEDMAN | RUBIN  
1126 Highland Ave.  
Bremerton, WA 98337  
Telephone: (360) 782-4300  
Fax: (360) 782-4358  
E-mail: rfriedman@friedmanrubin.com

22  
23 <sup>565</sup> Exhibit A to Mullenix Declaration (Daniels Deposition) at 220:22-221:2.

<sup>566</sup> PT-72 at 8.

1 **CERTIFICATE OF SERVICE**

2 I hereby certify that on \_\_\_\_\_, 2013, that a copy of the foregoing document was  
3 hand delivered for filing with the Superior Court, Kitsap County with a copy e-mailed and  
4 mailed, via First Class Mail, to the following:

5 Jeffrey R. Johnson, Esq.  
6 Scheer & Zehnder, LLP  
7 701 Pike Street, Suite 2200  
8 Seattle, WA 98101

9 *Attorneys for Defendant Intuitive Surgical Inc.*

10 And a copy mailed to the following:

11 Allen J. Ruby  
12 Skadden, Arps, Slate, Meagher & Flom  
13 525 University Ave.  
14 Palo Alto, CA 94301

15 *Attorneys for Defendant Intuitive Surgical Inc.*

16 Dated this \_\_\_\_\_ day of \_\_\_\_\_, 2013.

17 \_\_\_\_\_  
18 Dana C. Watkins